Hierarchical models for semi-competing risks data with application to
  quality of end-of-life care for pancreatic cancer by Lee, Kyu Ha et al.
ar
X
iv
:1
50
2.
00
52
6v
2 
 [s
tat
.A
P]
  5
 A
ug
 20
15
Hierarchical models for semi-competing risks
data with application to quality of end-of-life
care for pancreatic cancer
Kyu Ha Lee∗
Epidemiology and Biostatistics Core, The Forsyth Institute
and
Francesca Dominici
Department of Biostatistics, Harvard T.H. Chan School of Public Health
and
Deborah Schrag
Department of Medical Oncology, Dana Farber Cancer Institute
and
Sebastien Haneuse
Department of Biostatistics, Harvard T.H. Chan School of Public Health
August 6, 2015
Abstract
Readmission following discharge from an initial hospitalization is a key marker
of quality of health care in the United States. For the most part, readmission
has been studied among patients with ‘acute’ health conditions, such as pneumo-
nia and heart failure, with analyses based on a logistic-Normal generalized linear
mixed model (Normand et al., 1997). Na¨ıve application of this model to the study
of readmission among patients with ‘advanced’ health conditions such as pancre-
atic cancer, however, is problematic because it ignores death as a competing risk.
A more appropriate analysis is to imbed such a study within the semi-competing
risks framework. To our knowledge, however, no comprehensive statistical methods
have been developed for cluster-correlated semi-competing risks data. To resolve this
gap in the literature we propose a novel hierarchical modeling framework for the
analysis of cluster-correlated semi-competing risks data that permits parametric or
non-parametric specifications for a range of components giving analysts substantial
∗This work was supported by National Cancer Institute grant (P01 CA134294-02) and National Insti-
tutes of Health grants (ES012044, K18 HS021991, R01 CA181360-01).
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flexibility as they consider their own analyses. Estimation and inference is performed
within the Bayesian paradigm since it facilitates the straightforward characterization
of (posterior) uncertainty for all model parameters, including hospital-specific ran-
dom effects. Model comparison and choice is performed via the deviance information
criterion and the log-pseudo marginal likelihood statistic, both of which are based
on a partially marginalized likelihood. An efficient computational scheme, based on
the Metropolis-Hastings-Green algorithm, is developed and had been implemented
in the SemiCompRisks R package. A comprehensive simulation study shows that the
proposed framework performs very well in a range of data scenarios, and outperforms
competitor analysis strategies. The proposed framework is motivated by and illus-
trated with an on-going study of the risk of readmission among Medicare beneficiaries
diagnosed with pancreatic cancer. Using data on n=5,298 patients at J=112 hospi-
tals in the six New England states between 2000-2009, key scientific questions we
consider include the role of patient-level risk factors on the risk of readmission and
the extent of variation in risk across hospitals not explained by differences in patient
case-mix.
Keywords: Bayesian survival analysis; cluster-correlated data; illness-death models; re-
versible jump Markov chain Monte Carlo; shared frailty; semi-competing risks
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1 Introduction
Cancer of the pancreas is one of the most deadly. In 2013, an estimated 38,460 in-
dividuals died from pancreatic cancer in the United States making it the fourth most
prevalent cause of cancer death (American Cancer Society, 2013). Unfortunately, since
there are no effective screening tests for pancreatic cancer, most patients are diagnosed
at a late stage of the disease, specifically once it has metastasized to other parts of the
body. As a result, survival is poor with 1-year and 5-year mortality rates are of 75%
and 94%, respectively (Shin and Canto, 2012). In practice, since prognosis is poor and
mortality rates high, the treatment and management of patients diagnosed with pancre-
atic cancer generally focuses on palliative care aimed at enhancing quality of end-of-life
care (PLoS Medicine Editors, 2012). Such care is expensive, however, with patients diag-
nosed with pancreatic cancer accruing an estimated $165,000 in health care costs in their
last year of life (Mariotto et al., 2011).
Despite the huge costs, there are currently no comprehensive national efforts to monitor
quality of end-of-life care for pancreatic cancer nor for any of a broad range of other
‘advanced’ health conditions for which the management of disease focuses on palliative
care. Outside the context of these conditions, however, there is substantial interest in
understanding variation in quality of health care. The recent literature, in particular, has
focused on readmission as a key marker of quality of care, in part because it is expensive but
also because it is thought of as an often-preventable event (Vest et al., 2010; Warren et al.,
2011; Brooks et al., 2014; Stitzenberg et al., 2015). In addition, as the nation’s largest payer
of health care costs in the United States, the Centers for Medicare and Medicaid Services
(CMS) uses hospital-specific readmission rates as a central component in two programs: the
Hospital Inpatient Quality Reporting Program, which requires hospitals to annually report,
among other measures, readmission rates for pneumonia, heart failure and myocardial
infarction in order to receive a full update to their reimbursement payments (CMS, 2013a);
and, the Readmission Reduction Program, which requires CMS to reduce payments to
hospitals with excess readmissions (CMS, 2013b).
Across all of these efforts, investigations of readmission in the literature have invariably
used a logistic-Normal generalized linear mixed model (LN-GLMM) to analyze patients
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clustered within hospitals (Normand et al., 1997; Ash et al., 2012). While reasonable for
health conditions with effective treatment options and low mortality, direct application of
this model to investigate variation in risk of readmission following a diagnosis of pancreatic
cancer is inappropriate because of the strong force of mortality. Consider, for example,
n=5,298 Medicare beneficiaries diagnosed with pancreatic cancer at J=112 hospitals in
six New England states between 2000-2009 and suppose interest lies in understanding
determinants of readmission 90 days post-discharge. While additional detail is given below,
we note at the outset that 1,257 patients (24%) died within 30 days of discharge without
experiencing a readmission event; furthermore, 1,912 patients (36%) died within 90 days
of discharge without experiencing a readmission event. Na¨ıve application of a standard
LN-GLMM to these data ignores the fact that a substantial portion of the patients are not
at risk to experience the event of ‘readmission by 90 days’ for much of the timeframe. Such
an analysis may lead to bias and, if incorporated into existing CMS programs, could have
a major impact on how hospitals are penalized for poor quality of care.
In the statistics literature, data that arise from studies in which primary scientific in-
terest lies with some non-terminal event (e.g. readmission) whose observation is subject
to a terminal event (e.g. death) are referred to as semi-competing risks data (Fine et al.,
2001). Broadly, published methods for the analysis of semi-competing risks data can be
classified into three groups: methods that specify dependence between the non-terminal
and terminal events via a copula (Fine et al., 2001; Peng and Fine, 2007; Hsieh et al.,
2008); methods based on multi-state models that induce dependence via a shared patient-
specific frailty (Kneib and Hennerfeind, 2008; Xu et al., 2010; Zeng et al., 2012; Han et al.,
2014; Zhang et al., 2014; Lee et al., 2015); and, methods based on principal stratifica-
tion (Zhang and Rubin, 2003; Egleston et al., 2007; Tchetgen Tchetgen, 2014). Common
to all of these methods, however, is that their development has focused exclusively on
settings where individual study units are independent. As such, the methods are not de-
sign to address scientific questions that arise naturally in the context of cluster-correlated
data (Diggle et al., 2002; Fitzmaurice et al., 2012). In the context of readmission following
a diagnosis of pancreatic cancer, such questions include: (i) the investigation of between-
and within-hospital risks factors for readmission while acknowledging death as a competing
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force, (ii) characterizing and quantifying between-hospital variation in risk of the terminal
event not explained by differences in patient case-mix, and (iii) estimating, and quantifying
uncertainty for, hospital-specific effects, as well as ranking. Furthermore, it is well-known
that if one is to perform valid inference all potential sources of correlation must be ac-
counted for in the analysis.
To our knowledge, while the literature on the related competing risks problem has con-
sidered methods for cluster-correlated data settings (Katsahian et al., 2006; Chen et al.,
2008; Gorfine and Hsu, 2011; Zhou et al., 2012; Gorfine et al., 2014), only one paper on
the analysis of cluster-correlated semi-competing risks data has been published. Specifi-
cally, Liquet et al. (2012) recently proposed a multi-state model that incorporated a hospital-
specific random effect to account for cluster-correlation. Estimation and inference was per-
formed within the frequentist paradigm, based on an integrated likelihood that marginalizes
over the random effect, implemented in the frailtypack R package (Rondeau et al., 2012).
For our purposes, however, their approach is limited in a number of important ways. First,
the analyses presented in Liquet et al. (2012) permit either a patient-specific frailty to ac-
count for dependence between T1 and T2 or a hospital-specific random effect to account
for cluster-correlation but not both simultaneously. Second, the proposed specification as-
sumed that the hospital-specific random effect for the non-terminal event is independent of
the hospital-specific random effect for the terminal event, precluding a potentially impor-
tant form of dependence. Third, towards understanding variation in risk of readmission,
the hospital-specific random effects are themselves key parameters of scientific interest and
not nuisance parameters to be marginalized over. Finally, evaluation of the integrated like-
lihood requires the specification of a parametric distribution for the hospital-specific ran-
dom effects. While estimation and inference for regression parameters is generally robust
to misspecification of random effects distributions in GLMMs, misspecification is known
to adversely impact the shape of the estimated distribution of the random effects them-
selves (McCulloch et al., 2011; McCulloch and Neuhaus, 2011; Neuhaus and McCulloch,
2011). This is particularly important in quality of health care studies where identifying
a hospital as being in the tail of the distribution can have a substantial impact on their
evaluation.
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Towards overcoming these limitations, we develop a novel, comprehensive hierarchical
multi-state modeling framework for cluster-correlated semi-competing risks data. A key
feature of the framework, and its implementation, is that it permits either parametric or
non-parametric specifications for a range of model components, including baseline hazard
functions and distributions for hospital-specific random effects. This gives analysts substan-
tial flexibility as they consider their own analyses. Estimation and inference is performed
within the Bayesian paradigm which facilities the straightforward quantification of uncer-
tainty for all model parameters, including hospital-specific random effects and variance
components. The remainder of this paper paper is organized as follows. Section 2 intro-
duces an on-going study of readmission among patients diagnosed with pancreatic cancer,
and provides a description of the available Medicare data. Section 3 describes the proposed
framework, including specification of prior distributions; Section 4 provides a brief overview
of an efficient computational algorithm for obtaining samples from the joint posterior, its
implementation and methods for comparing goodness-of-fit across model specifications.
Section 5 presents a comprehensive simulation study investigating the performance of the
proposed framework, including a comparison with the methods of Liquet et al. (2012). Sec-
tion 6 reports on a detailed analysis of the motiving pancreatic cancer study; sensitivity
analyses regarding the specification of certain model parameters are reported in Section
7. Finally Section 8 concludes the paper with a discussion. Where appropriate, detailed
derivations and additional results are provided in an online Supplementary Materials doc-
ument.
2 Risk of Readmission Among Patients Diagnosed with
Pancreatic Cancer
As mentioned in the Introduction, readmission is a key marker of quality-of-care (Ash et al.,
2012; CMS, 2013a,b). To-date, however, studies of readmission have focused on health
conditions that have relatively good prognosis and/or low mortality including heart fail-
ure, myocardial infarction and pneumonia (Krumholz et al., 1997, 2011; Joynt et al., 2011;
Epstein et al., 2011). Beyond these conditions, however, little is known about variation
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in risk of readmission for patients diagnosed with terminal conditions such as pancreatic
cancer. We are therefore currently engaged in a collaboration investigating readmission
among Medicare enrollees diagnosed with pancreatic cancer. The overarching goals of the
study are to improve end-of-life quality of care for these patients by first understanding
patient-level risk factors associated with readmission and second understanding variation in
risk at the level of the hospital (i.e. that not explained by differences in patient case-mix).
Towards this we identified all n=5,298 Medicare enrollees who were diagnosed with pancre-
atic cancer during a hospitalization at one of J=112 hospitals in the six New England states
(Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont) between
2000-2009. Information on the initial hospitalization and diagnosis, patient characteristics
and co-morbid conditions, discharge destination and subsequent readmissions is obtained
from the Medicare Fee-For-Service inpatient claims file (Part A). Specific covariates of in-
terest include sex (0/1 = male/female), age, race (0/1 = white/non-white), the patients
Charlson/Deyo comorbidity score (Sharabiani et al., 2012), information on entry route for
the initial admission (0/1 = from the ER/transfer from some other facility), whether or not
the patient underwent a pancreatic cancer-specific procedure (resection, bypass, or stent),
the length of hospitalization and the discharge destination. For the latter, patients could
have been discharged to their home, their home with care, a hospice, an intermediate care or
skilled nursing facility (ICF/SNF) or some other facility (e.g. a rehabilitation facility or to
inpatient care). Table 1 provides a summary of observed distributions for these covariates.
Also provided in Table 1 is a summary of the observed outcome information at 30
and 90 days post-discharge. Specifically, each patient is classified into one of four groups:
(1) they experienced a readmission event and were subsequently observed to die; (2) they
experienced a readmission event but were censored prior to death; (3) they were observed
to die without having experienced a readmission event; and, (4) they were censored prior to
experiencing either a readmission or death event. The administrative censoring at 30 and
90 days is driven by a several important factors. First, scientific and health policy interest
regarding readmission has generally focused on a patient’s experience in the immediate
months following discharge (CMS, 2013a). The primary rationale for this is that post-
discharge management for patients diagnosed with pancreatic cancer generally focuses on
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Table 1: Covariate and outcome information for n=5,298 Medicare beneficiaries diagnosed with
pancreatic cancer in the six New England states during a hospitalization between 2000-2009.
Outcome information is considered with administrative censoring applied at 30 and 90 days post-
discarge.
n Percent
Covariate information
Sex Female 3,037 57.3
Male 2,261 42.7
Age, years 65-69 727 13.7
70-74 1,052 19.9
75-79 1,226 23.1
80-84 1,129 21.3
≥ 85 1,164 20.0
Race White 4,982 94.0
Non-white 316 6.0
Charlson/Deyo comorbidity score ≤ 1 4,854 91.6
> 1 444 8.4
Entry route Emergency room 2,255 42.6
Transfer from another facility 3,043 57.4
Procedure during hospitalization Yes 1,291 24.4
No 4,007 75.6
Length of hospitalization, days 1-7 3,170 59.8
8-14 1,465 27.7
≥ 15 663 12.5
Discharge destination Home 1,823 34.4
Home with care 1,571 29.7
Hospice 419 7.9
SNF/ICF 1,219 23.0
Other facility 266 5.0
Outcome information with administrative censoring at 30 days
Readmission and death 205 3.9
Readmission and censored prior to death 853 16.1
Death without readmission 1,257 23.7
Censored prior to readmission or death 2,983 56.3
Outcome information with administrative censoring at 90 days
Readmission and death 608 11.5
Readmission and censored prior to death 930 17.6
Death without readmission 1,912 36.1
Censored prior to readmission or death 1,848 34.9
palliative care, with a specific emphasis on pain management. As patients and their health
care providers coordinate this care, the early phases are particularly important for long-
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term success and are therefore of key interest. A second consideration is that readmission
events that occur soon after a patient is discharged are more likely to be directly related
to their diagnosis and subsequent care. Readmission events that occur a long time after
diagnosis are less likely to be directly related to the quality of care they receive in the
immediate aftermath of the diagnosis and, arguably, should not count against a hospitals
performance.
Censored prior to readmission or death
Death without readmission
Readmssion and censored
Readmission and death
0
20
40
60
80
10
0
Figure 1: Hospital-specific distributions of the outcome information for n=5,298 Medicare benefi-
ciaries diagnosed with pancreatic cancer at one of J=112 hospitals in the six New England states
between 2000-2009. Outcomes have been administratively censored at 90 days and distributions
ordered according to the observed percentage of deaths (with and without readmission).
A central feature of the Medicare data is that the n=5,298 patients are clustered within
J=112 hospitals; cluster sizes vary from 10-420 with a median of 30 patients. The inherent
clustering of patients within hospitals is important from both a statistical and a scientific
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perspective: valid inference requires acknowledging potential correlation among patients
and understanding between-hospital variation in readmission rates is a key scientific goal.
Towards the latter, Figure 1 provides a barplot of the hospital-specific distributions of the
four outcome groups based on censoring at 90 days. While there are many ways in which the
J=112 hospitals could be ordered, Figure 1 orders them according to the total percentage of
patients readmitted within 90 days (i.e. with or without a subsequent death event). From
the figure we see that there is substantial variation in observed readmission rates across
hospitals, with the lowest being 5.6% and the highest being 64.3%. Moving beyond these
raw adjusted rates would need to first account for case-mix differences across the hospitals,
second account for death as a competing risk and third account for the cluster-correlation.
3 A Bayesian Framework for Cluster-Correlated Semi-
competing Risks Data
3.1 Model specification
Viewing ‘discharge’, ‘readmission’ and ‘death’ as three states, the underlying data gener-
ating mechanism that gave rise to these data can be represented by a multi-state model,
specifically an illness-death model (Andersen et al., 1993; Putter et al., 2007; Xu et al.,
2010). Letting T1 denote the time to non-terminal event and T2 the time to the terminal
event, the illness-death model is characterized by three hazard functions that govern the
rates at which patients transitions between the states:
h1(t1) = lim
∆→0
1
∆
Pr[T1 ∈ [t1, t1 +∆)| T1 ≥ t1, T2 ≥ t1], t1 > 0 (1)
h2(t2) = lim
∆→0
1
∆
Pr[T2 ∈ [t2, t2 +∆)| T1 ≥ t2, T2 ≥ t2], t2 > 0 (2)
h3(t2|t1) = lim
∆→0
1
∆
Pr[T2 ∈ [t2, t2 +∆)| T1 = t1, T2 ≥ t2], t2 > t1. (3)
In practice, analyses based on the illness-death model characterized by (1)-(3) proceeds
by placing structure on these functions, specifically as a function of covariates and frail-
ties/random effects. Towards this, let Tji1 and Tji2 denote the time to the non-terminal
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event and time to the terminal event for the ith patient in the jth cluster, respectively,
for i = 1, . . . , nj and j = 1, . . . , J . Furthermore, let Xjig be a vector of time-invariant
covariates for the ith patient in the jth cluster that will be considered in the model for the
gth transition, g=1,2,3. Consider the following general modeling specification:
h1(tji1; γji,Xji1, Vj1) = γji h01(tji1) exp{XTji1β1 + Vj1}, tji1 > 0 (4)
h2(tji2; γji,Xji2, Vj2) = γji h02(tji2) exp{XTji2β2 + Vj2}, tji2 > 0 (5)
h3(tji2|tji1; γji,Xji3, Vj3) = γji h03(tji2|tji1) exp{XTji3β3 + Vj3}, tji2 > tji1, (6)
where γji is a shared patient-specific frailty, Vj = (Vj1, Vj2, Vj3) is a vector of cluster-
specific random effects, each specific to one of the three possible transitions, and βg is
a transition-specific vector of fixed-effect log-hazard ratio regression parameters. As de-
scribed by Xu et al. (2010), model (6) is often simplified in practice by either assuming
that h03(tji2|tji1) = h03(tji2) or that h03(tji2|tji1) = h03(tji2− tji1). Given the former specifi-
cation, the model is referred to as beingMarkov in the sense that the hazard for death given
readmission does not depend on the actual time of readmission; under the latter specifica-
tion, the model is referred to as semi-Markov. For simplicity we focus the exposition in this
section on Markov models although note that the methods and computational algorithms
have also been developed and implemented for the semi-Markov model; the analyses in
Sections 6 and 7 also consider both models.
3.2 The observed data likelihood
To complete the notation developed so far, let Cji denote the right censoring time for the
ith patient in the jth cluster. Furthermore, let Yji1 = min(Tji1, Tji2, Cji), ∆ji1 = 1 if Yji1
= Tji1 (i.e. a readmission event is observed) and 0 otherwise, Yji2 = min(Tji2, Cji) and,
∆ji2 = 1 if Yji2 = Tji2 (i.e. a death event is observed) and 0 otherwise. Finally, let Dji =
{yji1, δji1, yji2, δji2} denote the observed outcome data for the ith patient in the jth cluster
and H0g(·) the cumulative baseline hazard function corresponding to h0g(·). Let ~γ and ~V
denote the collections of the γji and Vj, respectively. Following Putter et al. (2007), for a
given specification of (4)-(6), the observed data likelihood as a function of the unknown
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parameters Φ = {β1,β2,β3, h01, h02, h03, ~γ, ~V }, is given by:
L(D|Φ) =
J∏
j=1
nj∏
i=1
L(Dji|β1,β2,β3, h01, h02, h03, γji,Vj)
=
J∏
j=1
nj∏
i=1
{γjih01(yji1)ηji1}δji1(1−δji2)
{
γ2jih01(yji1)ηji1h03(yji2)ηji3
}δji1δji2
×{γjih02(yji2)ηji2}(1−δji1)δji2 exp {−γjir(yji1, yji2)} , (7)
where ηjig = exp{XTjigβg+Vjg} and r(tji1, tji2) = [H01(tji1)ηji1+H02(tji1)ηji2+{H03(tji2)−
H03(tji1)} ηji3].
In the remainder of this section, we complete the specification of the Bayesian model
by providing detail on a range of possible choices for specification of the baseline hazard
functions in (4)-(6), the population distribution for the hospital-specific random effects
and, finally, prior distributions. To facilitate the exposition, Table 2 provides a summary
of four possible specifications of the model along with the hyperparameters that require
specification by the analyst.
Table 2: Summary of four models based on parametric and non-parametric specifications of the
baseline hazard functions and hospital-specific random effects distributions. Hyperparameters
that require specification by the analyst are provided in parenthesis. Note, (aθ, bθ), the hyper-
parameters for the patient-specific frailty variance component, require specification in all of four
models.
Hospital-specific random effects, Vj
MVN DPM†
Baseline hazard functions, h0g(·) (Ψv, ρv) (Ψ0, ρ0, τ)
Weibull (aα,g, bα,g, aκ,g, bκ,g) Weibull-MVN Weibull-DPM
PEM† (αKg , aσ,g, bσ,g) PEM-MVN PEM-DPM
† PEM: piecewise exponential model; DPM: Dirichlet process mixture
3.3 Baseline hazard functions
Within the frequentist paradigm estimation and inference for time-to-event models is often
based on a partial likelihood which conditions on risk sets, removing the need for analysts
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to specify baseline hazard functions. In the Bayesian paradigm, however, one is required to
specify these functions. Here, we consider two strategies. The first assumes that the under-
lying transition times follow Weibull(αw,g, κw,g) distributions, parameterized so that h0g(t)
= αw,gκw,gt
αw,g−1. While such a parametric specification is appealing due to its computa-
tional simplicity, especially in small-sample settings, the Weibull is somewhat restrictive in
that the corresponding hazard function is strictly monotone. As an alternative, we consider
a non-parametric specification based on taking each of the log-baseline hazard functions
to be a flexible mixture of piecewise constant functions (McKeague and Tighiouart, 2000).
Briefly, let sg,max denote the maximum observed time for transition g and partition (0,
sg,max] into Kg + 1 intervals: sg = {sg,0, sg,1, . . . , sg,Kg+1}, with sg,0 ≡ 0 and sg,Kg+1 ≡
sg,max. Given the partition (Kg, sg), we assume
log h0g(t) = λg(t) =
Kg+1∑
k=1
1[sg,k−1<t≤sg,k]λg,k, (8)
where λg,k is the (constant) height of the log-baseline hazard function on the interval
(sg,k−1, sg,k]. We refer to this specification as a piecewise exponential model (PEM) for
the baseline hazard function. Note, while numerous options are available for specifying
these functions (e.g. Ibrahim et al., 2001), a key benefit of this structure is that it balances
flexibility and computational convenience, since the integrals in the likelihood (specifically
for the cumulative hazard functions) are replaced with summations (Lee et al., 2015).
3.4 Hospital-specific random effects
As with specification of the baseline hazard functions, we consider two options for the spec-
ification of the population distribution for the J hospital-specific vectors of random effects.
First, motivated by the current standard for analyses of readmission (i.e. a LN-GLMM), we
consider a specification in which the Vj arise as i.i.d draws from a mean-zero multivariate
Normal distribution with variance-covariance matrix ΣV . The diagonal elements of the
3×3 matrix ΣV characterize variation across hospitals in risk for readmission, death and
death following readmission, respectively, that is not explained by covariates included in
the linear predictors. Crucially, that each random effect has its own variance component
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allows the characterization of differential variation across hospitals for each of the three
transitions. In addition, the off-diagonals of ΣV permit covariation between the three ran-
dom effects across the hospitals giving researchers the ability to characterize, for example,
whether or not hospitals with high mortality rates tend to have low readmission rates.
While conceptually simple and computationally convenient, the Normal distribution
it is often criticized as being a strong assumption. As an alternative we consider the
use of a so-called Bayesian nonparametric specification for the population distribution of
Vj, specifically a Dirichlet process mixture of multivariate Normal distributions (DPM-
MVN) (Ferguson, 1973; Bush and MacEachern, 1996; Walker and Mallick, 1997). One
representation of this model is as follows:
Vj|µj,Σj ∼ MVN3(µj,Σj),
µj,Σj |G ∼ G,
G ∼ DP (G0, τ), (9)
where µj ,Σj are the cluster-specific latent mean and variance of Vj, which are taken to be
draws from some (unknown) distribution G to which a Dirichlet process prior is assigned.
Finally the Dirichlet process is indexed by G0, the so-called centering distribution, and τ ,
the so-called precision parameter.
3.5 Hyperparameters and prior distributions
The proposed Bayesian framework is completed with the specification of prior distributions
for unknown parameters introduced in Sections 3.1-3.4.
3.5.1 Stage one parameters
For each of the transition-specific regression parameters, βg for g=1,2,3, a non-informative
flat prior on the real line is adopted. For the shared patient-specific frailties, γji, we assume
that they arise from a Gamma(θ−1, θ−1) distribution, parameterized so that E[γji] = 1
and V [γji] = θ. In the absence of prior knowledge on the frailty variance component, a
Gamma(aθ, bθ) hyperprior for the precision θ
−1 is adopted.
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3.5.2 Baseline hazard functions
For the parametric Weibull baseline hazard functions, since the hyperparameters have sup-
port on (0,∞), we complete the specification of this model by adopting gamma prior distri-
butions for both; that is, we take αw,g ∼ Gamma(aα,g, bα,g) and κw,g ∼ Gamma(aκ,g, bκ,g),
g=1,2,3.
To complete the non-parametric PEM model specification, we specify that the Kg + 1
heights arise from a multivariate Normal distribution. Specifically, letting λg = (λg,1,. . . ,
λg,Kg , λg,Kg+1) denote the transition-specific heights, we assume that λg ∼ MVN(µλg1,
σ2λgΣλg), where µλg is the overall mean, σ
2
λg
is a common variance component for the Kg+1
elements andΣλg is a correlation matrix. To induce a priori smoothness in the baseline haz-
ard functions we view the components of λg in terms of a one-dimensional spatial problem,
so that adjacent intervals can ‘borrow’ information from each other. To do this we spec-
ify Σλg via a Gaussian intrinsic conditional autoregression (ICAR)(Besag and Kooperberg,
1995). Additional technical details regarding the corresponding MVN-ICAR are provided
in Supplementary Materials A. Finally, we specify a series of hyperpriors for the additional
parameters introduced in the MVN-ICAR. In particular, we adopt a flat prior on the real
line for µλg and a conjugate Gamma(aσ,g, bσ,g) distribution for the precision σ
−2
λg
. For the
ICAR specification, we avoid reliance on a fixed partition of the time scales by permitting
the partition (Kg, sg) to vary and be updated via a reversible jump MCMC scheme (Green,
1995). Towards this we first adopt a Poisson(αKg) prior for the number of splits in the
partition, Kg. Conditional on the number of splits, we take the locations to be a priori
distributed as the even-numbered order statistics:
π(sg|Kg) ∝ (2Kg + 1)!
∏Kg+1
k=1 (sg,k − sg,k−1)
(sg,Kg+1)
(2Kg+1)
, (10)
Jointly, these choices form a time-homogeneous Poisson process prior for the partition (Kg,
sg) so that a posteriori, after mixing over partitions as they arise in the MCMC scheme, the
value of λg(t) in any given small interval of time is characterized as a smooth exponentiated
mixture of piecewise constant functions (Arjas and Gasbarra, 1994; McKeague and Tighiouart,
2000; Haneuse et al., 2008).
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3.5.3 Hospital-specific random effects
For the parametric specification of a single MVN3(0, ΣV ) distribution, we adopt a conju-
gate inverse-Wishart(Ψv , ρv) prior for the variance-covariance matrix ΣV . Completion of
the non-parametric DPM-MVN model requires specification of prior choices for the cen-
tering distribution and the precision parameter. Here we take G0 to be a multivariate
Normal/inverse-Wishart (NIW) distribution for which the probability density function can
be expressed as the product:
fNIW(µ,Σ|Ψ0, ρ0) = fMVN (µ|0,Σ)× finv−Wishart(Σ|Ψ0, ρ0),
where fD(·|θD) is the density function for a distribution D indexed by θD. This choice is
appealing in that one can exploit prior-posterior conjugacy in the MCMC scheme (Neal,
2000). Finally, we treat hyperparameter the precision parameter in DPM-MVN specifica-
tion, τ , as unknown and assign a Gamma(aτ , bτ ) hyperprior (Escobar and West, 1995).
4 Posterior Inference and Model Comparison
4.1 Markov Chain Monte Carlo
To perform estimation and inference for each of the models in Table 2 we use a random scan
Gibbs sampling algorithm to generate samples from their joint posterior distributions. In
the corresponding Markov chain Monte Carlo (MCMC) scheme, parameters are updated by
either exploiting conjugacies inherent to the model structure or using a Metropolis-Hastings
step. For models that adopt a PEM specification for the baseline hazard functions, updating
the partition (Kg, s) requires a change in the dimension of the parameter space and a
Metropolis-Hastings-Green step is used (Green, 1995). A detailed description of proposed
computational scheme is given in Supplementary Materials B; as mentioned in Section 3.1,
the computation scheme has been developed for both the Markov and semi-Markov models
for h03(·).
Finally, we note that the algorithms are implemented in the SemiCompRisks package for
R (R Development Core Team, 2014). Given the complexity of the proposed models, and
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the numerous updates in the MCMC scheme, C has been used as the primary computational
engine to ensure that analyses can be conducted within a reasonable timeframe.
4.2 Model comparison
In practice, analysts have to balance model complexity with the realities of sample size
and availability of information. While each of models in Table 2 has its own merit and
utility, it may be of interest to directly compare their goodness of fit to the observed
data. To this end, we consider two model assessment metrics: the deviance information
criterion (DIC; Spiegelhalter et al., 2002), and the log-pseudo marginal likelihood statis-
tic (LPML; Geisser and Eddy, 1979; Gelfand and Mallick, 1995). Although DIC is often
the default choice for model comparison in the Bayesian paradigm, its use in the context
of complex hierarchical models requires care (Celeux et al., 2006). Specifically for models
that condition on latent parameters, such as the patient-specific γji in models (4)-(6), DIC
computed on the basis of a likelihood that is marginalized with respect to these parameters
performs more reliably as a metric for comparison than DIC computed on the basis of a
likelihood that conditions on them (Millar, 2009). For our purposes, since the Vj random
effects are of intrinsic scientific interest, we propose to evaluate DIC and LPML on the
basis of a partially marginalized likelihood, one that integrates solely over the distribution
of the patient-specific frailties:
L∗(D|Φ∗) =
∫ J∏
j=1
nj∏
i=1
L(Dji|β1,β2,β3, h01, h02, h03, γ,Vj)fθ(γ; θ)dγ (11)
where Φ∗ = {β1,β2,β3, h01, h02, h03, θ, ~V }, L(Dji|·) is given by expression (7) and f(·; θ) is
the density of a Gamma(θ−1, θ−1) distribution (see Section 3.5.1).
Given expression (11), we therefore compute DIC as:
DIC = D(Φ∗) + 2pD, (12)
whereD(Φ∗) =
∑
j,i
−2 logL∗(Dji|Φ∗) is the (marginal) deviance and Φ∗ is the posterior mean
of Φ∗. The penalty term, pD, is given by D(Φ
∗) − D(Φ∗), where D(Φ∗) is the posterior
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mean of D(Φ∗). Note, a model with smaller DIC indicates a better fit of the model for the
data.
The LPML statistic is computed as
∑
j,i
log(CPO)ji, the sum of the logarithms of the
patient-specific conditional predictive ordinate (CPO) (Geisser, 1993), each defined as:
CPOji = L
∗(Dji|D(−ji)) =
∫
L∗(Dji|Φ∗)π(Φ∗|D(−ji))dΦ∗, (13)
where D(−ji) denotes the data with the observation from the ith patient in the jth cluster
removed. Intuitively, the CPOji is the posterior probability of the observed outcome for i
th
patient in the jth cluster, i.e. (yji1, δji1, yji2, δji2), on the basis of a model fit to a dataset
that excludes that particular patient. Thus, large values of CPOji attribute high posterior
probability to the observed data and, therefore, indicate a better fit. Although a closed form
expression for CPOji is not available for our proposed models, following Shao and Ibrahim
(2000) we approximate CPOji via a Monte Carlo estimator:
(
1
Q
Q∑
q=1
L∗(Dji|Φ∗(q))−1
)−1
, (14)
where {Φ∗(q); q = 1, 2, . . . , Q} are MCMC samples drawn from the (marginal) joint posterior
distribution of Φ∗.
5 Simulation Studies
The performance of the proposed models is investigated through a series of simulation
studies. The overarching goals of the simulation studies are to investigate the small sample
operating characteristics of the models summarized in Table 2 under a variety of scenarios
as well as to compare their performance with the methods of Liquet et al. (2012).
5.1 Set-up and data generation
Towards developing a comprehensive understanding of the performance of the proposed
methods we consider six data scenarios that vary in terms of the true underlying baseline
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hazard distributions, the true distribution of the cluster-specific random effects and the
true extent of variation in the patient-specific frailties. Table 3 provides a summary. In
scenarios 1-5, the baseline hazard functions are set to correspond to the hazard of a Weibull
distribution so that the event rates in the simulated data are similar to those in the ob-
served Medicare data when the outcomes are administratively censored at t=90; specifically,
we set (αw,1, κw,1)=(0.8, 0.05), (αw,2, κw,2)=(1.1, 0.01), and (αw,3, κw,3)=(0.9, 0.01). To
evaluate the performance of the model when the baseline hazard functions do not corre-
spond to a Weibull, scenario 6 takes them to be piecewise linear functions: h0g(t) = {(kg-
bg)t/40+bg}I(t≤40) + {(3kg-bg)/2-(kg-bg)t/80}I(t>40), with b1=0.1, b2=0.05, b3=0.15, and
k1=k2=k3=0.0005 specified so that the true baseline hazard functions are not monotone
increasing or decreasing functions like a Weibull.
Table 3: Summary of six simulation scenarios explored in Section 5.
Scenario Distribution of Distribution of
baseline hazard functions cluster-specific random effects, Vj θ
1 Weibull MVN(0, 0.25·I) 0.50
2 Weibull MVN(0, 0.25·I) 1.00
3 Weibull MVN
(
0,
[
0.25 −0.10 −0.10−0.10 0.25 0.20−0.10 0.20 0.25
])
0.50
4 Weibull MVN(0, 0.25·I) 0.00
5 Weibull 0.5·MVN(0, I)+0.5·MVN(0, 0.01·I) 0.50
6 Piecewise linear MVN(0, 0.25·I) 0.50
With regard to the ‘true’ distribution of the cluster-specific random effects, scenarios
1, 2, 4 and 6 consider a multivariate Normal distribution in which the components are
independent. Scenario 3 expands on this by considering the impact of covariation across
the Vj, while Scenario 5 examines the performance of the models when the true distribution
is a mixture of two multivariate Normal distributions.
Finally, with regard to the ‘true’ variance of the patient-specific frailties, scenarios 1,
3, 5 and 6 consider a base value of θ=0.5. This value was chosen as a compromise across
the posterior medians from the fits of the four models in Table 2 to the Medicare data (see
Table 9 below). Scenario 2 considers the impact of greater variation in the patient-specific
frailties, while Scenario 4 corresponds to a misspecification of the proposed model with the
‘true’ θ set to 0.
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For each of the six scenarios we generated R=500 simulated datasets under the semi-
Markov illness-death model described in Section 3.1. Across all simulated datasets, we
set the number of clusters and cluster-specific sample sizes to be those observed in the
Medicare data. Furthermore, we specified that each of the three transition-specific haz-
ard functions depended on three covariates: Xjig,1 and Xjig,2 both Normal(0, 1) random
variables and Xjig,3 a Bernoulli(0.5) random variable. The regression coefficients are set to
β1=β2=(0.5, 0.8, -0.5) and β3=(1.0, 1.0, -1.0), so that the covariate effects on the risk of
the terminal event depend on whether or not the non-terminal event has occurred. Finally,
we note that the function used to simulate the semi-competing risks data is available in
the SemiCompRisks package.
5.2 Analyses
For each of the R=500 datasets under each of the six scenarios we fit each of the four models
in Table 2. For the proposed models in which the baseline hazard function was specified via
a Weibull distribution, we set (aα,g, bα,g) = (0.5, 0.01) and (aκ,g, bκ,g) = (0.5, 0.05) for the
transition-specific shape and rate parameters. For models in which a non-parametric PEM
specification was adopted for the baseline hazard function, we set the prior Poisson rate
on the number of intervals to be αg = 10. For the precision parameter in the MVN-ICAR
specification, we set (aσ,g, bσ,g) = (0.7, 0.7) so that the induced prior for σ
2
λg
had a median
of 1.72 and 95% central mass between 0.23 and 156.
For the variance component associated with the patient-specific frailties, we set (aθ,
bθ) = (0.7, 0.7); that is the same prior was used for the precision θ
−1 for the γji frailties
as the precision component in the MVN-ICAR specification for the PEM model. For the
hospital-specific random effects variance components, given a MVN specification, we set
(Ψv, ρv) = (I3, 5) so that the induced prior on ΣV has a prior mean given by the 3×3
identity matrix. The same prior was adopted for the variance-covariance matrix of the
centering distribution of the DPM-MVN specification, G0; that is, we set (Ψ0, ρ0) = (I3,
5). Finally, for the precision parameter in the DPM-MVN specification we set (aτ , bτ ) =
(1.5, 0.0125) so that a priori τ had a mode of 40 and standard deviation of 98. Given
the prior specifications, two independent chains were run for a total of six million scans
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each; the Gelman-Rubin potential scale reduction (PSR) statistic (Gelman et al., 2013)
was used to assess convergence, specifically requiring the PSR to be less than 1.05 for all
model parameters.
In addition to the models in Table 2, we analyzed each simulated dataset using the
methods of Liquet et al. (2012). Specifically, we considered the ‘shared frailty’ (SF) model
implemented in the frailtypack package for R (Rondeau et al., 2012) and summarized us-
ing notation consistent with that adopted in this manuscript in Supplementary Materials
Section C. Briefly, this model adopts a Cox-type regression structure for each transition-
specific hazard, as we do in expressions (4)-(6). For the baseline hazard functions, two
options are available: one that corresponds to a Weibull distribution and another where
each hg(·) is specified via a flexible penalized smoothing spline. To distinguish these mod-
els, we refer to them as the Weibull-SF and Spline-SF models, respectively. In contrast
to the specification in (4)-(6), the SF model introduces a cluster-specific frailties as a mul-
tiplicative factors for each transition-specific hazard. Two options are available for the
distribution of these factors across the clusters; either they arise from three independent
gamma distributions or they arise from three independent log-Normal distributions. For
either option, estimation and inference is performed within the frequentist paradigm specif-
ically based on an integrated likelihood that marginalizes out the cluster-specific frailties;
estimation of the latter is performed via empirical Bayes. In this paper, we present the
results from the SF models that adopt independent gamma distributions for cluster-specific
frailties while we provide those from the SF models with independent log-Normal frailties
in Supplementary Materials D. Finally, we note that in contrast to the specification in
expressions (4)-(6), the SF model does not account for within-patient correlation. That
is there is no quantity that corresponds to the patient-specific γji terms in the proposed
models.
5.3 Results
5.3.1 Baseline survivor functions
Figure 2 presents the mean estimated transition-specific baseline survival functions under
scenarios 1, 4 and 6 across the six models. Under scenarios 1 and 4, for which the baseline
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hazard functions are Weibull, all four of the proposed models estimate the three baseline
survivor functions very well. In contrast the two SF models only perform well in scenario
4 for which θ=0. This is to be expected since, as described in detail in Supplementary
Materials Section C, the SF model does not include patient-specific frailties; effectively,
it assumes that θ=0 even when it is not. In scenario 6, for which the baseline hazard
functions are not Weibull, the proposed PEM-MVN and PEM-DPM specifications capture
the true shape of the baseline survivor functions well; all four of the models that assume
the baseline hazard function to be a Weibull, however, are unable to capture the shape.
5.3.2 Regression parameters and θ
Focusing on scenarios 1-3, each corresponding to a ‘true’ Weibull-MVN model, Table 4
indicates that all four of the proposed models in Table 2 perform very well in terms of
estimation and inference for β1 and θ. Across the board, we find that percent bias is
no larger than 3.2% and the estimated coverage probabilities are all close to the nominal
0.95. In contrast, both the Weibull-SF and Spline-SF models yield point estimates of β1
that are significantly biased and, as such, have poor coverage probabilities. The poor
performance of the SF models is likely tied to the fact that they do not account for within-
patient correlation; hence θ is not estimated by these models. The results for these models,
however, is dramatically improved under scenario 4 for which the true value of θ is zero (i.e.
the scenario they explicitly accommodate). Interestingly, the four proposed models each
exhibit a small amount of bias under this scenario (up to approximately 5%). In addition
the coverage probabilities for β11 and β12 are poor, particularly for the two models that
adopt a PEM specification for the baseline hazard function. In scenario 5, we again see
that all four of the proposed models perform well. Finally, under scenario 6 we see that
the PEM-MVN and PEM-DPM models perform very well in terms of bias and coverage.
In contrast, the Weibull-MVN and Weibull-DPM models perform poorly, particularly with
respect to estimation of θ, illustrating the potential danger of adopting a parametric Weibull
baseline hazard function when the truth is not a Weibull.
While Table 4 explores estimation and the (valid) quantification of uncertainty, Table
5 examines the relative merits of the various analysis approaches in terms of efficiency.
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Table 4: Estimated percent bias and coverage probability for β1 and θ for six analyses described in Section 5.2, across six simulation
scenarios given in Table 3. Throughout values are based on results from R=500 simulated datasets.
Percent Bias Coverage Probability
Scenario True Weibull Weibull Weibull PEM PEM Spline Weibull Weibull Weibull PEM PEM Spline
value -MVN -DPM -SF -MVN -DPM -SF -MVN -DPM -SF -MVN -DPM -SF
β11 0.50 0.1 0.2 -19.8 0.4 0.4 -21.0 0.96 0.96 0.01 0.95 0.96 0.00
1 β12 0.80 0.2 0.3 -19.7 0.5 0.4 -21.0 0.95 0.95 0.00 0.96 0.97 0.00
β13 -0.50 0.3 0.3 -19.8 0.3 0.3 -21.2 0.97 0.96 0.31 0.96 0.96 0.25
θ 0.50 1.0 1.3 1.4 1.2 0.95 0.95 0.93 0.94
β11 0.50 -0.1 -0.0 -31.8 0.1 0.1 -32.8 0.94 0.94 0.00 0.94 0.93 0.00
2 β12 0.80 0.1 0.2 -31.7 0.4 0.3 -32.7 0.97 0.97 0.00 0.94 0.95 0.00
β13 -0.50 1.2 1.3 -31.1 1.1 1.1 -32.2 0.94 0.95 0.05 0.94 0.94 0.04
θ 1.00 0.4 0.7 0.7 0.6 0.94 0.95 0.94 0.95
β11 0.50 0.3 0.3 -19.9 0.7 0.7 -21.0 0.94 0.94 0.00 0.93 0.94 0.00
3 β12 0.80 0.4 0.4 -19.8 0.8 0.8 -20.9 0.94 0.94 0.00 0.94 0.94 0.00
β13 -0.50 0.4 0.3 -20.1 0.5 0.6 -21.2 0.96 0.96 0.31 0.95 0.96 0.27
θ 0.50 2.0 2.1 3.2 3.2 0.96 0.96 0.93 0.95
β11 0.50 3.7 3.7 0.2 4.7 4.6 0.3 0.87 0.86 0.96 0.81 0.83 0.96
4 β12 0.80 3.6 3.6 -0.0 4.5 4.5 0.1 0.80 0.79 0.95 0.69 0.70 0.95
β13 -0.50 4.0 4.0 0.2 4.8 4.7 0.2 0.93 0.94 0.94 0.93 0.93 0.93
θ 0.00
β11 0.50 -0.3 0.1 -20.3 0.0 0.3 -21.1 0.94 0.95 0.00 0.96 0.96 0.00
5 β12 0.80 0.0 0.3 -20.0 0.3 0.6 -20.9 0.95 0.95 0.00 0.96 0.96 0.00
β13 -0.50 -0.2 0.2 -20.4 -0.2 0.2 -21.3 0.94 0.94 0.29 0.94 0.94 0.25
θ 0.50 -0.2 1.0 0.4 1.3 0.95 0.95 0.95 0.96
β11 0.50 9.3 9.4 -22.1 0.4 0.3 -25.9 0.58 0.57 0.00 0.94 0.94 0.00
6 β12 0.80 9.7 9.8 -22.0 0.5 0.5 -25.8 0.20 0.20 0.00 0.94 0.95 0.00
β13 -0.50 10.2 10.2 -21.6 0.8 0.7 -26.1 0.81 0.80 0.21 0.93 0.94 0.10
θ 0.50 52.8 53.0 1.8 1.7 0.00 0.00 0.95 0.96
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Figure 2: Estimated transition-specific baseline survival functions, S0g(·) = exp(−H0g(·)), for
each six analyses described in Section 5.2 under simulation scenarios 1, 4 and 6.
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Table 5: Average relative width of 95% credible/confidence intervals for β1 and θ, with the
Weibull-MVN model taken as the referent, across six simulation scenarios given in Table 3.
Throughout values are based on results from R=500 simulated datasets.
Scenario Weibull Weibull Weibull PEM PEM Spline
-MVN -DPM -SF -MVN -DPM -SF
β11 1.00 1.00 0.81 1.02 1.02 0.81
1 β12 1.00 1.00 0.77 1.04 1.04 0.77
β13 1.00 1.00 0.84 1.00 1.01 0.83
θ 1.00 1.00 1.10 1.12
β11 1.00 1.00 0.73 1.02 1.02 0.73
2 β12 1.00 1.00 0.69 1.03 1.04 0.69
β13 1.00 1.00 0.76 1.00 1.00 0.76
θ 1.00 1.00 1.12 1.14
β11 1.00 1.00 0.81 1.02 1.02 0.81
3 β12 1.00 1.00 0.76 1.04 1.04 0.77
β13 1.00 1.00 0.83 1.00 1.01 0.83
θ 1.00 1.00 1.10 1.13
β11 1.00 1.00 0.95 1.02 1.01 0.96
4 β12 1.00 1.00 0.94 1.03 1.03 0.95
β13 1.00 1.00 0.96 1.01 1.01 0.96
θ 1.00 1.00 1.09 1.09
β11 1.00 1.00 0.81 1.02 1.02 0.81
5 β12 1.00 1.00 0.77 1.03 1.03 0.77
β13 1.00 1.00 0.83 1.00 1.00 0.83
θ 1.00 1.00 1.09 1.09
β11 1.00 1.00 0.74 0.94 0.95 0.73
6 β12 1.00 1.00 0.72 0.96 0.97 0.71
β13 1.00 1.00 0.76 0.93 0.93 0.75
θ 1.00 1.00 0.89 0.90
Specifically, we computed the average relative width of 95% credible/confidence intervals
for β1 and θ under each analysis with the Weibull-MVN model taken as a common ref-
erent. Comparing the Weibull-DPM to the Weibull-MVN as well as the results between
the PEM-MVN and PEM-DPM we see that there is no loss of efficiency for any of the
regression parameters, and minimal loss for θ, if one adopts the flexible DPM specification
for the cluster-specific random effects, even if the true distribution is a MVN. Under all
five scenarios for which the true baseline hazard functions were Weibull hazard functions,
the two models that adopt a PEM specification have somewhat wider credible intervals
particularly for θ. However, as expected, the 95% credible intervals for the two PEM mod-
els under scenario 6 are somewhat tighter indicating improved efficiency when the true
baseline hazard functions are not Weibull hazard functions. Finally, across all scenarios,
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the estimated 95% confidence intervals for the two SF models are substantially tighter than
those for any of the proposed analyses, although this must be balanced with the high bias
shown in Table 4.
5.3.3 Cluster-specific random effects
Finally, Table 6 investigates the relative performance of the various analyses with respect
to estimation of the cluster-specific random effects. Specifically, we calculated the mean
squared error of prediction (MSEP) given by:
1
RJ
R∑
r=1
J∑
j=1
(Vˆrjg − Vrjg)2, (15)
where Vrjg is the cluster-specific random effect for the j
th cluster in the transition g for the
rth simulated data set, r=1,. . . ,R. For each of the four proposed models, Vˆrjg was taken as
the corresponding posterior median. For the two SF models, Vˆrjg was taken as a the log of
the empirical Bayes estimates of the transition/cluster-specific frailties (see Supplementary
Materials C for details). We note, however, that for some of the simulated datasets, the
empirical Bayes estimates returned by the current implemented in the frailtypack package
were zero. Since taking the log of these estimates would yield Vˆrjg = −∞, we calculated
MSEP over the random effects for which the empirical Bayes estimate was non-zero; to
place these values in context, Table 6 also reports the percentage of instances where a
frailty was estimated to be zero.
From Table 6 we see that under scenarios 1-4, for which the true model is aWeibull-MVN
model, the Weibull-MVN analysis generally performs the best. Comparing the Weibull-
MVN and PEM-MVN results across these scenarios, we see that over-specification of the
baseline hazard functions (i.e. adoption of the more flexible PEM specification) does not
meaningfully impact MSEP. In addition, comparing the Weibull-MVN and Weibull-DPM
results we see that over-specification of the random effects structure (i.e. adoption of the
more flexible DPM specification) does not adversely affect MSEP either. When the true
distribution of the random effects is not a multivariate Normal distribution, however, as in
scenario 5, both the Weibull-DPM and PEM-DPM models outperform their MVN coun-
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Table 6: Mean squared error of prediction (×10−2) for cluster-specific random effects based on six
analyses described in Section 5.2, across six data scenarios given in Table 3. Throughout values
are based on results from R=500 simulated datasets.
Scenario Weibull Weibull Weibull PEM PEM Spline
-MVN -DPM -SF -MVN -DPM -SF
%F† %F
V1 5.25 5.27 6.40 5.27 5.27 6.39
1 V2 7.66 7.70 8.70 17.8 7.67 7.72 8.68 0.2
V3 9.91 9.95 12.13 9.91 9.96 12.11
V1 6.36 6.41 8.10 6.37 6.41 8.09
2 V2 8.76 8.85 10.23 10.4 8.77 8.86 10.20 0.0
V3 11.13 11.19 13.85 11.13 11.19 13.91
V1 5.03 5.04 6.27 5.04 5.04 6.22
3 V2 6.34 6.34 8.28 15.8 6.36 6.36 8.24 0.0
V3 7.55 7.49 11.66 7.57 7.55 11.69
V1 3.84 3.85 4.99 3.87 3.87 5.01
4 V2 6.25 6.27 7.19 12.8 6.25 6.27 7.12 0.4
V3 7.89 7.90 9.57 7.90 7.91 9.52
V1 6.95 6.26 10.87 6.96 6.27 10.86
5 V2 11.52 10.50 14.95 12.8 11.50 10.52 14.92 0.2
V3 15.46 14.66 25.04 15.46 14.72 24.94
V1 5.05 5.01 6.34 4.89 4.85 6.26
6 V2 7.58 7.55 8.60 5.4 7.41 7.39 8.49 1.4
V3 6.72 6.65 13.42 6.44 6.40 13.70
† % of times SF models yield at least one of Vˆj being −∞, resulting in MSEP being ∞
terparts, illustrating the potential benefit of the more flexible DPM specification. Further-
more, when the true baseline hazard functions do not correspond to a Weibull distribution,
the MSEP for the two PEM models are, as expected, smaller than the corresponding val-
ues for the two Weibull models, illustrating the potential benefit of the more flexible PEM
specification. Finally, we find that the empirical Bayes estimates of the cluster-specific
random effects from the SF models perform relatively poorly when compared to the corre-
sponding estimates from the proposed methods. For example, the Spline-SF model yields
approximately 14% to 55% higher MSEP than our proposed PEM-MVN model across the
six scenarios.
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6 Analysis of Medicare Data
6.1 Analysis details and prior specifications
Returning to the motivating application of readmissions following a diagnosis of pancre-
atic cancer, we fit each of the four models summarized in Table 2 to the Medicare data
under both the Markov and semi-Markov assumption for h3(·) (see Section 3.1). Based on
the rationale provided in Section 2, we administratively censored observation time at 90
day. Given the results from the simulation studies, specifically with respect to estimation
of the cluster-specific random effects, we decided not to fit the shared frailty models of
Liquet et al. (2012). We did, however, perform an analysis based on a LN-GLMM model
since this model is the current standard for analyzing variation in the risk of readmission
and we believed it would be instructive to examine the potential impact of ignoring death
as a competing force. Towards this, let Y ∗ji = 0/1 be a binary indicator of whether or not
the ith patient in the jth hospital readmitted within 90 days of discharge. Note, if a patient
died prior to readmission within 90 days their outcome was set to Y ∗ji = 0. The LN-GLMM
is then given by:
logit Pr(Y ∗ji = 1|X∗ji, V ∗j ) = X∗Tji β∗ + V ∗j (16)
where V ∗j is a hospital-specific random effect for readmission taken to be Normally dis-
tributed with mean zero and a constant variance, σ2v . To complete the Bayesian specifica-
tion of this model, we adopted a Gamma(0.7, 0.7) prior for the precision σ−2v . For the four
proposed models, the hyperparameters outlined in Table 2 are specified as in Section 5.2
Throughout the analyses, to ensure the baseline hazard functions in the proposed mod-
els and the (overall) intercept in the LN-GLMM retained reasonable interpretations, age
was standardized so that ‘zero’ corresponded to age 77 years and a one-unit increment
corresponded to a 10-year contrast. Furthermore, length of stay during the initial hos-
pitalization was also standardized so that ‘zero’ corresponded to 10 days and a one-unit
increment corresponded to a 7-day contrast.
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6.2 MCMC
Towards obtaining summaries of the joint posterior distributions we ran 3 independent
chains of the proposed MCMC scheme, each for a total of 6 million scans. Convergence
was evaluated by inspection of trace plots as well as calculation of the PSR statistic; an
MCMC scheme was determined to have converged if the PSR statistic was less than 1.05 for
all parameters in the model (see Supplementary Materials E). Although the hierarchical
models are complex and include a large number of parameters, the proposed algorithm
achieved an overall acceptance rate of 35% across the various Metropolis-Hastings and
Metropolis-Hastings-Green steps. To provide a sense of computational time, the most
complex of our proposed models (i.e. the PEM-DPM model), the implementation in our
R package is able to generate 1 million scans in 30 minutes on a 2.5 GHz Intel Core i7
MacBook Pro; for the least complex of the models (i.e. the Weibull-MVN model), the
implementation is able to generate 1 million scans in 10 minutes on the same machine.
6.3 Results
6.3.1 Overall model fit
Table 7 provides DIC and LPML for the eight model fits. For the DIC measure, a general
rule of thumb for model comparison is to consider differences of less than 2 to be negligible,
differences between 2 and 6 to indicative of positive support for the model with the lower
value and differences greater than 6 to be strong support in value of the model with the lower
value (Spiegelhalter et al., 2002; Millar, 2009). For LPML, one can compute the so-called
pseudo Bayes factor (PBF) for two models by exponentiating difference in their LPML
values (Hanson, 2006). While the conventional Bayes factor (Kass and Raftery, 1995) tends
to find which model explains the observed data best, predictive methods such as PBF
attempt to find which model gives the best predictions for future observations when the
same process as the original data is used to generate the observations (Kadane and Lazar,
2004)
Based on pairwise comparisons of the values in Table 7 we draw a number of conclu-
sions. First, each of the models in which a semi-Markov specification is made for h03(·)
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Table 7: DIC and LPML for eight models fit to the New England Medicare data.
DIC LPML
Weibull-MVN 46184.3 -23101.6
Markov Weibull-DPM 46174.1 -23101.2
PEM-MVN 45609.2 -22812.6
PEM-DPM 45606.8 -22810.7
Weibull-MVN 46163.7 -23088.8
semi-Markov Weibull-DPM 46153.0 -23086.7
PEM-MVN 45574.1 -22790.9
PEM-DPM 45569.0 -22789.3
has a substantially better fit to the data than the corresponding model in which a Markov
assumption is made for h03(·); differences in DIC and the PBF range between 20.6-37.8
and the order of 105-109, respectively. Second, both DIC and LPML indicate that models
for which a PEM specification was adopted for the baseline hazard functions have substan-
tially better fit to the data than models for which a Weibull hazard function was adopted;
differences in DIC and the PBF range between 567.3-589.6 and the order of 10125-10129,
respectively. Finally, although DIC indicates a somewhat better fit for models that adopt
a DPM for the random effects distribution compared to a MVN specification, the LPML
values are less convincing in this regard; differences in DIC and the PBF range between
2.4-10.7 and 1.5-8.2, respectively.
6.3.2 Baseline survival functions
Since hazard functions are notoriously difficult to interpret, Figure 3 provides estimates
of the corresponding baseline survival functions. Specifically, they provide pointwise time-
specific posterior medians for S0g(·) for a 77-year old white female patient who had a
Charlson/Deyo comorbidity score of 0 or 1, whose initial hospitalization lasted 10 days
and during which they had no pancreatic cancer-related procedures, and were eventually
discharged to their own home. In panels (a)-(c) results are presented for models for which
a Markov assumption was adopted for h03(·); panels (d)-(f) present results for models for
which a semi-Markov assumption was adopted.
From panels (a) and (d) we see that all eight models indicate similar risk of readmis-
sion within the first 30 days. After 30 days, however, models with a parametric Weibull
30
Time since discharge, days
Ba
se
lin
e 
su
rv
iva
l f
un
ct
io
n
0.
0
0.
5
1.
0
0 30 60 90
Readmission
(a)
Weibull−MVN
Weibull−DPM
PEM−MVN
PEM−DPM
Time since discharge, days
0.
0
0.
5
1.
0
0 30 60 90
Death without readmission
(b)
Weibull−MVN
Weibull−DPM
PEM−MVN
PEM−DPM
Time since discharge, days
0.
0
0.
5
1.
0
0 30 60 90
Death after readmission
(c)
Weibull−MVN
Weibull−DPM
PEM−MVN
PEM−DPM
Time since discharge, days
Ba
se
lin
e 
su
rv
iva
l f
un
ct
io
n
0.
0
0.
5
1.
0
0 30 60 90
(d)
Weibull−MVN
Weibull−DPM
PEM−MVN
PEM−DPM
Time since discharge, days
0.
0
0.
5
1.
0
0 30 60 90
(e)
Weibull−MVN
Weibull−DPM
PEM−MVN
PEM−DPM
Time since readmission, days
0.
0
0.
5
1.
0
0 30 60 90
(f)
Weibull−MVN
Weibull−DPM
PEM−MVN
PEM−DPM
Figure 3: Estimated transition-specific baseline survival functions, S0g(·) = exp(−H0g(·)), for the
eight models fit to the New England Medicare data (see Table 7). Panels (a)-(c) are estimates
based on a Markov specification for h03(·); panels (d)-(f) are estimates based on a semi-Markov
specification. Note the difference in time scale between panels (c) and (d) due the differing
specifications for h03(·).
specification for the baseline hazard functions indicate substantially higher overall risk for
readmission. Note, most of the observed readmission events occur relatively soon after
discharge with a median of 18 days and 75% of observed events occurring within 40 days.
As such, the posterior mass is being assigned to values of the two Weibull hyperparameters,
(αg, κg), that fit the early time periods well to the detriment of fitting late periods relatively
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poorly. From panels (b) and (e) a similar phenomenon is observed for the baseline survival
function for death without readmission for which the median event time is 20 days and,
again, approximately 75% of observed events occurring within 40 days. In contrast, since
the distribution of time to death following readmission is more spread out (median=43
days, IQR=40 days) the estimated baseline survival functions under the Weibull and PEM
are more similar (see panels (c) and (f)).
6.3.3 Regression parameters
Posterior summaries for the vector of hazard ratio (HR) parameters for readmission, exp(β1),
are presented in Table 8. For brevity, based in part on the conclusions drawn from Table
7, results are only presented for models for which a semi-Markov specification was adopted
for h03(·); additional results, particularly for exp(β2) and exp(β3) are provided in Supple-
mentary Materials E. In addition, posterior summaries for the vector of odds ratio (OR)
parameters, exp(β∗) from model (16), are also presented.
Recognizing that the interpretation of the HR and OR parameters differ (due to the
different set of frailties/random effects that are conditioned upon), the results in Table
8 indicate that the LN-GLMM qualitatively identifies a different set of risk factors for
readmission than the results based on the proposed framework. For instance, while there
is evidence of lower risk for readmission among females diagnosed with pancreatic cancer
under the semi-competing risks approach (e.g. HR 0.80; 95% CI 0.70, 0.90 in Weibull-
MVN), one cannot draw the same conclusion based on the LN-GLMM (OR 0.91; 95% CI
0.80, 1.03). In addition, under the LN-GLMM model there is no evidence of a relationship
between source of entry to the initial hospitalization (OR 0.99; 95% CI 0.86, 1.14) while
under each of the semi-competing risks analysis models there is evidence that patients
who enter the initial hospitalization via some route other than the emergency room are at
higher risk of readmission (e.g. HR 1.12; 95% CI 1.00, 1.28). Conflicting results are also
found with respect to discharge destination. In particular, under the LN-GLMM model
patients who are discharged to home with care, a hospice, a ICF/SNF or some ‘other’
facility (e.g. a rehabilitation center) have statistically significant lower estimates odds of
readmission than patients discharged to their home without care. In contrast, results from
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Table 8: Posterior summaries (medians and 95% credible intervals (CI)) for hazard ratio (HR) parameters for readmission, exp(β1),
from semi-competing risks data analyses and odds ratios (OR) based on a LN-GLMM. For the latter, results are reported for models
for which a semi-Markov specification was adopted for h03(·)
LN-GLMM Weibull-MVN Weibull-DPM PEM-MVN PEM-DPM
OR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Sex
Male 1.00 1.00 1.00 1.00 1.00
Female 0.91 (0.80, 1.03) 0.80 (0.70, 0.90) 0.79 (0.70, 0.90) 0.85 (0.76, 0.96) 0.85 (0.76, 0.95)
Age† 0.87 (0.83, 0.92) 0.90 (0.86, 0.95) 0.90 (0.86, 0.95) 0.91 (0.87, 0.94) 0.91 (0.87, 0.95)
Race
White 1.00 1.00 1.00 1.00 1.00
Non-white 1.17 (0.90, 1.51) 1.12 (0.86, 1.45) 1.12 (0.86, 1.46) 1.11 (0.89, 1.40) 1.12 (0.89, 1.38)
Source of entry to initial hospitalization
Emergency room 1.00 1.00 1.00 1.00 1.00
Other facility 0.99 (0.86, 1.14) 1.18 (1.03, 1.36) 1.19 (1.03, 1.35) 1.12 (1.00, 1.27) 1.13 (1.00, 1.28)
Charlson/Deyo score
≤ 1 1.00 1.00 1.00 1.00 1.00
> 1 1.31 (1.05, 1.64) 1.50 (1.19, 1.85) 1.49 (1.20, 1.85) 1.41 (1.15, 1.68) 1.40 (1.15, 1.70)
Procedure during hospitalization
No 1.00 1.00 1.00 1.00 1.00
Yes 0.73 (0.61, 0.86) 0.45 (0.38, 0.53) 0.44 (0.37, 0.54) 0.56 (0.48, 0.66) 0.57 (0.48, 0.66)
Length of stay∗ 1.14 (1.06, 1.22) 1.15 (1.07, 1.24) 1.15 (1.07, 1.24) 1.12 (1.05, 1.18) 1.12 (1.05, 1.19)
Discharge location
Home without care 1.00 1.00 1.00 1.00 1.00
Home with care 0.68 (0.58, 0.79) 0.95 (0.82, 1.11) 0.96 (0.82, 1.11) 0.90 (0.79, 1.02) 0.89 (0.78, 1.02)
Hospice 0.06 (0.04, 0.10) 0.39 (0.22, 0.62) 0.39 (0.22, 0.62) 0.27 (0.15, 0.45) 0.27 (0.16, 0.43)
ICF/SNF 0.44 (0.36, 0.53) 0.88 (0.72, 1.07) 0.88 (0.73, 1.08) 0.76 (0.64, 0.90) 0.76 (0.65, 0.90)
Other 0.56 (0.41, 0.76) 1.04 (0.75, 1.42) 1.06 (0.75, 1.44) 0.91 (0.70, 1.18) 0.90 (0.68, 1.18)
† Standardized so that 0 corresponds to an age of 77 years and so that a one unit increment corresponds to 10 years
∗ Standardized so that 0 corresponds to 10 days and so that a one unit increment corresponds to 7 day
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the semi-competing risks analyses fail to indicate differences between patients discharged
to home without care and those discharged to home with care (e.g. HR 0.90; 95% CI
0.79, 1.02) or to some other facility. Furthermore, while patients discharged to either a
hospice or ICF/SNF have significantly lower odds of readmission, the estimated effects
are substantially attenuated (e.g. compare OR=0.06 under the LN-GLMM to HR=0.27
under the PEM-MVN model). Finally, consistent with the assessment of model fit in Table
7, Table 8 indicates that for estimation and inference for regression parameters differs
somewhat between models based on a Weibull baseline hazard specification and models
based on a PEM specification. Comparing the Weibull-MVN model to the PEM-MVN
model, for example, estimates for gender, Charlson/Deyo score and whether or not the
patient underwent a procedure during the hospitalization are all attenuated; in contrast
estimates for discharge location are generally strengthened under the PEM-MVN model,
in some cases achieving statistical significance.
6.3.4 Variance components
Table 9 provides posterior summaries for the standard deviation of the patient-specific
frailty distribution,
√
θ, as well as components of the variance-covariance matrix for the
hospital-specific V = (V1, V2, V3) from models in which a semi-Markov specification was
adopted for h03(·). For the latter, the summaries are directly with respect to the components
of ΣV under a MVN specification; under the two DPM specifications, posterior summaries
are reported for the marginal total variance-covariance matrix obtained by applying the
law of total cumulance:
∑J
j=1
{(
µmj − µ¯
)(
µmj − µ¯
)⊤
+ Σmj
}
/J , where µ¯ =
∑J
j=1µmj/J
(Ohlssen et al., 2007). From the Table we see that the components of variation (particu-
larly the standard deviation components) are generally smaller in magnitude for models in
which a PEM specification for the baseline hazard functions was adopted. For example, un-
der the Weibull-MVN model the posterior median of
√
θ is 1.03, whereas the corresponding
posterior median under the PEM-MVN model is 0.61. This is likely due to the γji patient-
specific frailties not only representing patient-level heterogeneity but also accounting, in
part, for misspecification of the Weibull model when the underlying baseline hazard func-
tions are not Weibull. Qualitatively, across all four model specifications, we find that there
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is less variation across hospitals in the random effects specific to readmission compared to
the random effects for mortality (either prior to or post-readmission); compare the pos-
terior summaries for SD(Vj1) to those of SD(Vj2) and SD(Vj2). Furthermore, while there
is no evidence of correlation between hospital-specific random effects for readmission and
corresponding random effects for mortality, there is some evidence of a positive correlation
between hospital-specific random effects for mortality pre- and post-readmission, although
the 95% CIs each cover 0.
Table 9: Posterior summaries (medians (PM) and 95% credible intervals (CI)) for standard devia-
tions (SD) of the underlying population distributions for the patient-specific frailties and hospital-
specific random effects. Estimates of population correlation components, between hospital-specific
random effects, are also provided.
Weibull-MVN Weibull-DPM PEM-MVN PEM-DPM
PM (95% CI) PM (95% CI) PM (95% CI) PM (95% CI)
Patient-specific
frailties√
θ 1.03 (0.94, 1.12) 1.03 (0.95, 1.12) 0.61 (0.50, 0.71) 0.61 (0.49, 0.71)
Hospital-specific
random effects
SD(Vj1) 0.26 ( 0.20, 0.34) 0.27 ( 0.21, 0.35) 0.25 ( 0.19, 0.32) 0.25 ( 0.20, 0.32)
SD(Vj2) 0.37 ( 0.28, 0.47) 0.37 ( 0.28, 0.47) 0.32 ( 0.25, 0.41) 0.32 ( 0.25, 0.42)
SD(Vj3) 0.37 ( 0.27, 0.50) 0.37 ( 0.27, 0.50) 0.33 ( 0.25, 0.44) 0.33 ( 0.25, 0.45)
corr(Vj1, Vj2) -0.04 (-0.40, 0.33) -0.04 (-0.40, 0.33) -0.12 (-0.44, 0.23) -0.12 (-0.45, 0.24)
corr(Vj1, Vj3) 0.06 (-0.32, 0.42) 0.06 (-0.32, 0.43) 0.03 (-0.32, 0.38) 0.03 (-0.33, 0.39)
corr(Vj2, Vj3) 0.39 (-0.02, 0.67) 0.37 (-0.03, 0.67) 0.28 (-0.12, 0.59) 0.29 (-0.11, 0.59)
6.3.5 Hospital-specific random effects
As noted, a key advantage of embedding the analysis of cluster-correlated semi-competing
risks data in the Bayesian framework is the relatively straightforward nature of obtaining
posterior summaries for the hospital-specific random effects themselves. Figure 4 provides
posterior medians and 95% CIs for V1j , j = 1, . . ., 112, based on the four models in
which a semi-Markov specification is adopted for h03(·). Note, across the four panels, the
ordering of the hospitals is based on the magnitude of the posterior median under the
Weibull-MVN model. Comparing the panels we see that posterior uncertainty for the V1j
is generally greater under models that adopt a DPM for the hospital-specific V compared
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to those that adopt a MVN specification. This may not be surprising given the additional
complexity of the DPM specification, although we do find that the more ‘complex’ PEM
specification for the baseline hazard functions yields lower posterior uncertainty than the
Weibull specification.
6.3.6 Hospital-specific ranks
In addition to examining the absolute values of the hospital-specific V1j , we also considered
their rank ordering. Figure 5 compares the ranks of the J=112 hospitals according to the
posterior median of V1j under the PEM-MVN model with a semi-Markov specification for
h03(·) to the corresponding ranks based on four other models: (a) LN-GLMM; (b) Weibull-
MVN with a semi-Markov specification for h03(·); (c) PEM-DPM with a semi-Markov
specification for h03(·); and, (d) PEM-MVN model with a Markov specification for h03(·).
In each panel, the grey horizontal and vertical lines mark the ‘top 10’ hospitals (i.e. ranks
1-10) and ‘bottom 10’ hospitals (i.e. ranks 103-112).
From panel (a) we see that the correspondence between the ranks under a semi-Markov
PEM-MVN model and those under a LN-GLMM it is far from exact. Crucially, from
the lower-left portion of the panel, three hospitals that would have been ranked in the
top 10 under the semi-Markov PEM-MVN model are ranked outside the top 10 under the
LN-GLMM (specifically, those marked with a ✳). Correspondingly there are three hospitals
(marked with a▲) who are indicated as being in the top 10 under the LN-GLMM while the
semi-competing risks analysis under the semi-Markov PEM-MVN would have ranked them
outside the 10 top. Furthermore, from the top-right portion of the panel, three hospitals
ranked in the bottom 10 under the semi-Markov PEM-MVN model are ranked above the
bottom 10 under the LN-GLMM model (i.e. those marked with a ▲).
From panels (b)-(d) we find that there is greater correspondence in the ranks of the 112
hospitals across the models within the proposed hierarchical framework. Comparing the
ranks under the semi-Markov PEM-MVN specification to the semi-Markov Weibull-MVN
specification in panel (b) we see that twos hospital that would have been ranked in the top
10 is now outside the top 10; there is also one hospital that is ranked in the bottom 10
under the semi-Markov PEM-MVN specification but outside the bottom 10 when a more
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Figure 4: Posterior summaries (median and 95% credible interval) for the hospital-specific random
effects for readmission, V1j , under four models for which a semi-Markov specification for h03(·)
was adopted. In each panel, the hospitals are ordered according to the posterior median under
the Weibull-MVN model.
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Figure 5: Comparison of ranks of J=112 hospitals in the Medicare data on the basis of the
posterior median for hospital-specific random effects for readmission, V1j . Panels compare the
ranks on the basis of one of four models to a referent set of ranks based on a PEM-MVN model
with a semi-Markov specification for h03(·) (see Section 6.3.6 for details). Hospitals marked with
a ✳ suffer under the given model compared to the referent under the referent semi-Markov PEM-
MVN model; hospitals marked with a ▲ benefit.
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restrictive Weibull model is used for the baseline hazard functions. Panels (c) and (d)
are qualitatively similar in that the same two hospitals switch ranks at the lower end and
the same two switch at the upper end; more generally, consistent with the conclusions we
draw from Table 7, there is very close correspondence in the ranks across the three models
represented in these two panels.
7 Sensitivity Analyses
As outlined in Section 3.5 and Table 2, the proposed Bayesian framework requires the spec-
ification of a number of hyperparameters. In practice comprehensive sensitivity analyses
should be conducted to examine the extent to which conclusions are robust with respect
to this specification, especially across key targets of estimation and inference. Here we
focus our attention on the choice of hyperparameters for the prior distribution of ΣV ,
the variance-covariance matrix of underlying population distributions for hospital-specific
random effects, and their influence on estimation/inference for the random effects as well
as τ , the precision parameter in the DPM specification of the baseline hazard function.
Towards this, we conducted sensitivity analyses based on the semi-Markov PEM-MVN
and PEM-DPM models, specifying a range of values for (Ψv, ρv) and (Ψ0, ρ0) such that
Ψv=Ψ0=Ψ
∗(ρ∗−4)I3 and ρv=ρ0=ρ∗, where, ψ∗=0.01, 0.1, 1, 10 and ρ∗=5, 10, 50, 100. Note,
these specifications correspond to a prior distribution for ΣV with a mean of ψ
∗I3 and a
variance of diagonal elements of 2ψ∗2/(ρ∗ − 6).
Table 10 presents the results. First, we focus Case I-IV, where ψ∗=1, ρ∗ = 100, 50, 10, 5
which correspond to prior distributions of ΣV having a mean of I3 and a standard deviation
of diagonal elements of 0.15, 0.21, 0.71, 3.16; for Case IV we note that the (induced) prior
standard deviation was calculated from 100,000 random draws from the prior. From the
results we see that when the prior distribution is centered around the identity matrix the
posterior assigns mass to smaller values of SD(Vj1) as one increases the prior variance
(dictated by decreasing ρ∗). This is likely due to the discrepancy between the actual
variation on the cluster-specific random effects for h1() and the choice the identity matrix,
I3, as the prior mean for ΣV (since ψ
∗=1) together with the strength attributed to that
choice (i.e. the prior variance for ΣV dictated by ρ
∗). When a prior mean of I3 is chosen for
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ΣV together with a high value of ρ
∗ the overall prior overcomes the information in the data
such that the posterior for SD(Vj1) is pushed ‘closer’ to 1.0. As ρ
∗ decreases, however, and
less prior mass is given to ΣV = I3, the likelihood is able to overcome the less informative
prior so that the posterior is able to move away from the prior mean. Interestingly, based on
both the DIC and LPML measures, we find that the overall fit of the data across Cases I-IV
improves as the prior variance increases. We therefore interpret these results collectively as
indicating that the variation across the (true underlying) Vj1 is meaningful but relatively
small. Turning to Cases V and VI, we note that the induced prior distributions of ΣV are
centered around relatively small values, specifically 0.01I3 and 0.1I3, with induced prior
standard deviations of diagonal elements of 0.07 and 0.22, respectively. From the DIC and
LPML values, these specifications of (Ψ∗, ρ∗) further improve the overall fit of the model
from Case IV, we the posterior summaries for SD(Vj1) again indicating that the variation
in the Vj1 is relatively small.
While there are clear differences in the posterior summaries for SD(Vj1) across Cases
I-VI, within each case we see that there is little difference in the corresponding summaries
between the MVN and DPM specifications; that is the conclusions one draws regarding
the variation of the true underlying Vj1 are robust to this choice. However we do find
that there are substantial differences in the average posterior standard deviations for the
J cluster-specific Vj1. In Case II, for example, σ¯Vj1 is 0.34 under the MVN specification
and 0.70 under the DPM specification. Generally, this ordering is consistent across the six
cases, as well as with the results presented in Figure 4. When combined with the posterior
summaries for SD(Vj1), the results suggest that for our application the trade-off of using the
more flexible DPM specification is somewhat detrimental to the analyses; use of the DPM
specification rather than the MVN does not serve to change our conclusions regarding the
variation across the true Vj1 but has, rather, served to increase the posterior uncertainty
regarding any given specific Vj1.
Finally, the last column of Table 10 presents the posterior median for τ , the precision
parameter in the DPM specification. If one interprets the DPM specification as a mixture
of MVN distributions (see Supplementary Materials Section B), τ dictates, in part, the
number of mixture components and, hence, the complexity of the overall specification.
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Table 10: Sensitivity analyses for prior specification for hospital-specific random effects. We obtain
the fits from PEM-MVN and in PEM-DPM conditioning on a range of values for (Ψv, ρv) and
(Ψ0, ρ0): Ψv=Ψ0=Ψ
∗(ρ∗ − 4)I and ρv=ρ0=ρ∗, where, ψ∗=0.01, 0.1, 1, 10 and ρ∗=5, 10, 50, 100.
For each model DIC, LPML, and posterior medians (PM) and 95% credible intervals (CI) for
standard deviations (SD) of the underlying population distributions for hospital-specific random
effects are reported, as well as the average posterior standard deviation of hospital-specific random
effects estimates on readmission (σ¯Vj1). Also presented are the PM for τ under the PEM-DPM
model.
Case (Ψ∗, ρ∗) Model DIC LPML
SD(Vj1) σ¯Vj1
τ
PM (95% CI) PM
I (1, 100)
MVN 45784.6 -22905.0 0.77 (0.69, 0.85) 0.36
DPM 45779.3 -22902.4 0.77 (0.70, 0.85) 0.70 0.14
II (1, 50)
MVN 45758.2 -22890.1 0.66 (0.59, 0.75) 0.34
DPM 45754.4 -22888.0 0.66 (0.59, 0.75) 0.72 0.14
III (1, 10)
MVN 45642.5 -22828.0 0.39 (0.33, 0.47) 0.27
DPM 45644.0 -22828.7 0.39 (0.33, 0.47) 0.47 0.14
IV (1, 5)
MVN 45574.1 -22790.9 0.25 (0.19, 0.32) 0.20
DPM 45569.0 -22789.3 0.25 (0.20, 0.32) 0.32 0.15
V (0.01, 5)
MVN 45549.4 -22777.8 0.08 (0.04, 0.16) 0.08
DPM 45550.6 -22778.8 0.09 (0.04, 0.18) 0.12 0.31
VI (0.1, 5)
MVN 45545.7 -22776.7 0.14 (0.09, 0.21) 0.13
DPM 45540.6 -22774.0 0.15 (0.10, 0.24) 0.18 0.23
From the results, however, we see that the posterior median of τ , which takes on values in
(0,∞), tends towards quite small values and is generally robust to the specification of (Ψ∗,
ρ∗). To further investigate the role of τ in our analyses, we conducted a series of additional
analyses where τ was fixed at values ranging from 0.1 to 100 (i.e. we did not adopt a gamma
hyperprior as described in Section 3.5.3). Although details are not reported here, we found
that results of our analyses to be very robust to the specific value of τ , again indicating
few gains associated with use of the more flexible DPM specification for our application.
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8 Discussion
In this paper, we propose a comprehensive, unified Bayesian framework for the analysis
of cluster-correlated semi-competing risks data. The framework is flexible in that it lets
researchers take advantage of the numerous benefits afforded by the Bayesian paradigm
including the natural incorporation of prior information and the straightforward quantifi-
cation of uncertainty for all parameters including hospital-specific random effects. The
framework is also flexible in that it gives researchers choice in adopting parametric and/or
semi-parametric specifications for various model components, a key consideration in prac-
tice when small sample size may require pragmatism during the analysis. To facilitate
model choice, we have also developed DIC and LMPL measures for model comparison
within the proposed framework. Finally, computationally efficient algorithms have been
developed and implemented, and are readily-available in a freely-available R package.
The work in this paper was motivated by an on-going collaboration investigating vari-
ation in risk of readmission following a diagnosis of pancreatic cancer. Towards this, we
applied the framework to a sample of 5,298 Medicare enrollees diagnosed with pancreatic
cancer at one of 112 hospitals between 2000-2009. The results from our analysis indi-
cate a number of important determinants of risk of readmission including gender, age,
co-morbidity status (as measured by the Charlson/Deyo score), whether or not they under
went a procedure during the index hospitalization, the length of stay of the index hospital-
ization and the location to which the patients was eventually discharged. The analyses also
revealed that there is substantially less between-hospital variation in risk of readmission
than the risk of death (either prior to or post-readmission), after accounting for patient
case-mix. To our knowledge these are the first reported results of this kind in the literature
and we are currently expanding our analyses to consider patients across the entire U.S.
More generally, in the clinical and health policy literature, the standard analysis ap-
proach for investigating risk of readmission is based on a LN-GLMM (Normand et al.,
1997; Ash et al., 2012). In the specific context of our application, compared with results
based on the proposed framework, such an analysis yields meaningfully different conclu-
sions regarding which patient-level characteristics are associated with risk of readmission,
the magnitude and statistical significance of those associations and the ranks of hospitals.
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Given the relative robustness across models within the proposed framework, the fact that a
LN-GLMM yields different conclusions is likely related to the fact that death is completely
ignored as a competing risk. As a concrete example consider the hospital in Figure 5(a) that
is ranked 8th under the semi-Markov PEM-MVN model and 26th under the LN-GLMM.
Closer inspection of the raw data reveals that very few patients diagnosed at this hospital
died within the 90-day window we consider. At other hospitals, the force of mortality is
stronger and patients die at higher rates within the 90-day window; that these patients die
is overlooked by the LN-GLMM which assumes that they remain ‘at risk’ to experience a
readmission event. Hence their estimated readmission rates are too small in the LN-GLMM
(since the denominator is erroneously inflated). Unfortunately the hospital ranked 8th un-
der the semi-Markov PEM-MVN model suffers from their low mortality rate in the sense
that they do not benefit from erroneous inflation of the readmission rate denominator, as
other hospitals do. Hence the change in rank.
As indicated, results across models within the proposed framework were relatively ro-
bust in our main application. We did find, however, that models which adopted the flexible
PEM specification for the baseline hazard functions had substantially better fit to the data
than models that adopted a Weibull specification. While models based on a semi-Markov
specification for death following readmission generally had better fit to the data than models
based on a Markov specification we note that this choice does not affect the interpretation
of the model for readmission (i.e. model (4)) the investigation of which was our primary
scientific goal. With this in mind, we have not reported on the results for the two models
for death (i.e. models (5) and (6)) although they are available in the Supplementary Mate-
rials E. In practice, researchers may be interested in readmission and death jointly in which
case the choice of specification for h03(·) will become critical from a scientific perspective
(Lee et al., 2015). In our main application, since the data are relatively rich in terms of
sample size and the event rates, we have taken the PEM-MVN and PEM-DPM models as
our primary models for comparison of ranks of hospitals and sensitivity analyses. In other
less-rich data settings, however, analysts may be in a position where structure is needed
either in the forms of the baseline hazard functions or for the random effects. Finally,
we note that in our application a MVN specification for the population distribution of
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the vector of hospital-specific random effects, Vj, appeared to be adequate. That is, the
so-called Bayesian non-parametric DPM specification did not yield any additional insight
into our understanding of variation in risk of readmission nor did it change meaningfully
the ranking of hospitals. In other applications this may, of course, not be the case and the
proposed framework gives researchers important choice in this regard.
In Section 5, we show that incorrect assumption of the underlying distribution for
cluster-specific random effects or baseline hazard functions result in lower efficiency of
the incorrect parametric estimators. In addition, the computational efficiency of proposed
models with non-parametric specification of parameters heavily depends on underlying
distributions of model parameters. For PEM models, if the underlying hazard function has
an intricate shape, the model estimates a posterior distribution αg to be centered around
a larger value, resulting in expensive computation due to more parameters (λg,k’s) to be
estimated. For DPM models, if data suggest a larger value of τ , the model will introduce
more latent classes in the mixture, implying more parameters to be estimated.
Our analysis focuses on readmission 90 days post-discharge. However, we note that the
computational performance of our proposed approach would not be challenged in the cases
when an administrative censoring is not imposed. In particular, the proposed PEM model
is flexible in that it allows the time scale for each of three hazard functions to be different
for each transition. Following McKeague and Tighiouart (2000) and Haneuse et al. (2008),
we suggest the last observed event time points be the upper bound in general problems
where an administrative censoring is not imposed. In our application, however, since most
of patients diagnosed with pancreatic cancer die within 1-year period, we would expect
the estimates of baseline hazard functions have a relatively greater uncertainty in the late
periods if the administrative censoring is not considered. In addition, in the context of our
study, patients can experience multiple readmission events prior to death. The literature
on recurrent event semi-competing risks would likely be useful for this setting and thus
the development of methods that can accommodate recurrent non-terminal events in the
cluster-correlated data setting is a promising area for future development.
The proposed hierarchical models assume constant hazard ratios over time conditional
on the cluster-specific and patient-specific random effects. Since the primary interest of
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our analysis is the study of readmission event within ‘short time frame’ (30 days or 90
days after discharge), the proportionality of hazards is quite reasonable assumption in our
application. In the literature of multi-state models, more rigorous diagnosis can be most
naturally done by considering a more flexible multi-state model such as a stratified model
or inclusion of non-proportional covariate effects (Hougaard, 2000). Expanding the scope
of the proposed models to include deviation from proportional hazards as well as time-
varying covariates is our future work. In this paper, we considered a gamma distribution
for the within-patient frailty because of its computational tractability. When the frailty
distribution is misspecified, the resulting estimator is not guaranteed to be consistent, with
the extent of asymptotic bias depending on the discrepancy between the assumed and true
frailties distributions. However, Hsu et al. (2007) studied the effect of mis-specification of
frailty distribution on the marginal regression estimates and hazard functions when gamma
distribution is assumed. Their results show that the biases are generally low, even when
the true frailty distribution is substantially different from the assumed gamma distribution.
Therefore, if the regression parameters and hazard function are of primary interest, the
gamma frailty model can be a reasonable choice in practice.
Finally, we conclude by emphasizing that the proposed framework significantly improves
and expands the set of statistical tools researches have to study quality of end-of-life care.
While our focus has been on pancreatic cancer, the proposed framework is broadly appli-
cable to all ‘advanced’ health conditions for which current treatment options are limited
and the force of mortality is strong. Such studies will be of paramount importance in
the near-future because many of these conditions, including other cancers as well as neu-
rodegenerative conditions such as Alzheimers’ disease, directly affect large segments of an
increasingly aging population. In addition, although it has not been in the focus of this pa-
per, the proposed framework will also be critical in helping policy-makers understand and
ultimately control the increasing costs of health care delivery in the U.S. In particular, the
proposed framework provides CMS appropriate statistical tools with which to expand the
scope of the Hospital Inpatient Quality Reporting Program and the Readmission Reduction
Program to include to conditions with strong forces of mortality.
SUPPLEMENTARY MATERIALS
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Title: In online Supplementary Materials, we provide a detail description of Metropolis-
Hastings-Green algorithm to fit our proposed models. Additional details regarding
the Medicare data and results from the application are also provided. (pdf file)
R-package ‘SemiCompRisks’: R-package SemiCompRisks contains codes to implement pro-
posed Bayesian framework described in the article. The package is currently available
in CRAN.
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1
Introduction
This document supplements the main paper titled “Hierarchical models for clustered
semi-competing risks data with application to pancreatic cancer”. In Section A, we provide
technical details regarding the MVN-ICAR specification for baseline hazard functions in
PEM models. In Section B, we provide a detailed description of the Metropolis-Hastings-
Green algorithm to implement our proposed Bayesian framework (Weibull-MVN, Weibull-
DPM, PEM-MVN, PEM-DPM). In Section C, we examine the potential use of methods
proposed in Gorfine and Hsu (2011) and Liquet et al. (2012) in the context of the mo-
tivating application. In Section D, we provide results from simulation studies that were
not presented in the main paper. Finally, Section E supplements our main paper with
some additional results from analyses of Medicare data from New England and a visual
assessment of convergence of the proposed MCMC schemes using potential scale reduction
factor.
In order to distinguish the two documents, alpha-numeric labels are used for sections,
tables, figures, and equations in this document while numeric labels are used in the main
paper.
2
A MVN-ICAR Specification for λg
In MVN-ICAR, the specification of a prior for the components of λg is considered as a one-
dimensional spatial problem. The dependence between neighboring intervals are modeled
via a Gaussian intrinsic conditional autoregression (ICAR) (Besag and Kooperberg, 1995).
Let λ
(−k)
g denote the vector given by λg with the k
th element removed. The full conditional
prior for λg,k is then taken to be the following normal distribution:
λg,k|λ
(−k)
g ∼ Normal(νg,k, σ
2
g,k), (1)
where the conditional mean, νg,k = µλg +
∑
j 6=kW
g
kj(λg,j − µλg), is a marginal mean plus a
weighted sum of the deviations of the remaining intervals. Let ∆¯gk = sg,k − sg,k−1 denote
the length of the Ig,k interval. We determine the weights for the intervals adjacent to the
kth intervals based on these lengths as follows:
W g
k(k−1) =
cλg(∆¯
g
k−1 + ∆¯
g
k)
∆¯gk−1 + 2∆¯
g
k + ∆¯
g
k+1
, W g
k(k+1) =
cλg(∆¯
g
k + ∆¯
g
k+1)
∆¯gk−1 + 2∆¯
g
k + ∆¯
g
k+1
, (2)
where the constant cλg ∈ [0, 1] dictates the extent to which λg,k is influenced by adjacent
intervals (Haneuse et al., 2008). The remaining weights corresponding to intervals which
are not directly adjacent to the kth interval are set to zero. The conditional variance σ2g,k
in (1) is given by σ2λgQ
g
k. The σ
2
λg
is an overall measure of variation across the elements of
λg and the diagonal matrix Q
g
k is given by
2
∆¯gk−1 + 2∆¯
g
k + ∆¯
g
k+1
. (3)
Given (1), (2), and (3), we can see that λg jointly follows a (Kg+1)-dimensional multivariate
normal (MVN) distribution:
MVNKg+1(µλg1, σ
2
λg
Σλg), (4)
where µλg is the overall (marginal) mean, σ
2
λg
the overall variability in elements of λg. The
Σλg is given by (I −W
g)−1Qg, where a (Kg + 1) × (Kg + 1) matrix W
g
(k,j)=W
g
kj and a
(Kg + 1)× (Kg + 1) diagonal matrix Q
g
(k,k)=Q
g
k.
3
B Metropolis-Hastings-Green Algorithm
B.1 Weibull models
Let ΦW = {αw,1, αw,2, αw,1, κw,1, κw,2, κw,3,β1,β2,β3, ~γ, ~V } be a set of parameters in the
likelihood function of Weibull models. The observed data likelihood LW (D|ΦW ) is given
by
J∏
j=1
nj∏
i=1
(
γjiαw,1κw,1y
αw,1−1
ji1 ηji1
)δji1(1−δji2) (
γ2jiαw,1κw,1y
αw,1−1
ji1 ηji1αw,3κw,3y
αw,3−1
ji2 ηji3
)δji1δji2
×
(
γjiαw,2κw,2y
αw,2−1
ji2 ηji2
)δji2(1−δji1)
exp {−rW (yji1, yji2)} , (5)
where ηjig = exp
(
x⊤jigβg + Vjg
)
and
rW (tji1, tji2)
=


γji
{
κw,1t
αw,1
ji1 ηji1 + κw,2t
αw,2
ji1 ηji2 +
(
κw,3t
αw,3
ji2 − κw,3t
αw,3
ji1
)
ηji3
}
, for Markov model
γji
[
κw,1t
αw,1
ji1 ηji1 + κw,2t
αw,2
ji1 ηji2 + {κw,3(tji2 − tji1)
αw,3} ηji3
]
, for semi-Markov model
For Weibull models, we use a random scan Gibbs sampling scheme, randomly selecting
and updating a (vector of) model parameter at each iteration.
B.1.1 Updating βg
Let Φ−(β) denote a set of parameters Φ with β removed. The full conditional posterior
distribution of β1 can be obtained by
π(β1|Φ
−(β1)
W , θ,ΣV ) ∝ LW (D|ΦW ).
∝
J∏
j=1
nj∏
i=1
exp
(
δji1x
⊤
ji1β1 − γjiκw,1y
αw,1
ji1 e
x⊤ji1β1+Vj1
)
.
Analogously, the full conditionals of β2 and β3 are given by
π(β2|Φ
−(β2)
W , θ,ΣV ) ∝
J∏
j=1
nj∏
i=1
exp
{
δji2(1− δji1)x
⊤
ji2β2 − γjiκw,2y
αw,2
ji1 e
x⊤ji2β2+Vj2
}
,
π(β3|Φ
−(β3)
W , θ,ΣV ) ∝
J∏
j=1
nj∏
i=1
exp
{
δji1δji2x
⊤
ji3β3 − γjiκw,3
(
y
αw,3
ji2 − y
αw,3
ji1
)
ex
⊤
ji3β3+Vj3
}
.
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Since the full conditionals do not have standard forms, we use Metropolis Hastings (MH)
algorithm to update each element of βg, βg,1, . . . , βg,p1. In our algorithm, the conventional
random walk MH is improved in convergence speed by taking some meaningful function of
the current value β
(t−1)
g,k for the mean and variance of Normal proposal density. Specifically,
let D1(βg,k) and D2(βg,k) denote the first and second gradients of log-full conditional of
βg with respect to βg,k, then a proposal β
∗ is drawn from a Normal proposal density
that is centered at µ(β
(t−1)
g,k ) = β
(t−1)
g,k −D1(β
(t−1)
g,k )/D2(β
(t−1)
g,k ), the updated value from the
Newton-Raphson algorithm, with a variance σ2(β
(t−1)
g,k ) = −2.4
2/D2(β
(t−1)
g,k ), based on the
inverse Fisher information evaluated with β
(t−1)
g,k (Roberts et al., 2001; Gelman et al., 2013).
Therefore, the acceptance probability for βg,k is given by
π(β∗g |Φ
−(βg)
W , θ,ΣV )Normal
(
β
(t−1)
g,k |µ(β
∗), σ2(β∗)
)
π(β
(t−1)
g |Φ
−(βg)
W , θ,ΣV )Normal
(
β∗|µ(β
(t−1)
g,k ), σ
2(β
(t−1)
g,k )
) , (6)
where β
(t−1)
g is a sample of βg at current iteration and β
∗
g is the βg with k-th element
replaced by β∗.
B.1.2 Updating αw,g
The full conditional posterior distribution of αw,1 is given by
π(αw,1|Φ
−(αw,1)
W , θ,ΣV )
∝ LW (D|ΦW )× π(αw,1)
∝ α
aα,1−1
w,1 e
−bα,1αw,1
J∏
j=1
nj∏
i=1
(
αw,1y
αw,1
ji1
)δji1 exp (γjiκw,1yαw,1ji1 ηji1) .
Analogously, the full conditionals of αw,2 and αw,3 are given by
π(αw,2|Φ
−(αw,2)
W , θ,ΣV ) ∝ α
aα,2−1
w,2 e
−bα,2αw,2
J∏
j=1
nj∏
i=1
(
αw,2y
αw,2
ji2
)δji2(1−δji1) exp (−γjiκw,2yαw,2ji1 ηji2) ,
π(αw,3|Φ
−(αw,3)
W , θ,ΣV ) ∝ α
aα,3−1
w,3 e
−bα,3αw,3
J∏
j=1
nj∏
i=1
(
αw,3y
αw,3
ji2
)δji1δji2
× exp
{
−γjiκw,3
(
y
αw,3
ji2 − y
αw,3
ji1
)
ηji3
}
.
In MH algorithm to update αw,g, we generate a proposal α
∗ from a Gamma distribution
with Gamma
(
(α
(t−1)
w,g )2/k0, α
(t−1)
w,g /k0
)
which corresponds to a distribution with a mean of
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α
(t−1)
w,g and a variance of k0. The value of k0 is specified such that the MH step for αw,g
achieves an acceptance rate of 25% ∼ 30%. Finally the acceptance probability to update
αw,g can be written as
π(α∗|Φ
−(αw,g)
W , θ,ΣV )G
(
α
(t−1)
w,g |(α∗w,g)
2/k0, α
∗
w,g/k0
)
π(α
(t−1)
w,g |Φ
−(αw,g)
W , θ,ΣV )G
(
α∗w,g|(α
(t−1)
w,g )2/k0, α
(t−1)
w,g /k0
) .
B.1.3 Updating κw,g
The full conditional posterior distribution of κw,g can be obtained by
π(κw,g|Φ
−(κw,g)
W , θ,ΣV ) ∝ LW (D|ΦW )× π(κw,g).
We see that the full conditionals of κw,g are gamma distributions and the samples can be
drawn from following distributions:
κw,1|Φ
−(κw,1)
W , θ,ΣV ∼ Gamma
(
J∑
j=1
nj∑
i=1
δji1 + aκ,1,
J∑
j=1
nj∑
i=1
γjiy
αw,1
ji1 ηji1 + bκ,1
)
,
κw,2|Φ
−(κw,2)
W , θ,ΣV ∼ Gamma
(
J∑
j=1
nj∑
i=1
δji2(1− δji1) + aκ,2,
J∑
j=1
nj∑
i=1
γjiy
αw,2
ji1 ηji2 + bκ,2
)
,
κw,3|Φ
−(κw,3)
W , θ,ΣV ∼ Gamma
(
J∑
j=1
nj∑
i=1
δji1δji2 + aκ,3,
J∑
j=1
nj∑
i=1
γji
(
y
αw,3
ji2 − y
αw,3
ji1
)
ηji3 + bκ,3
)
.
B.1.4 Updating γji
The full conditional posterior distribution of γji is given by
π(γji|Φ
−(γji)
W , θ,ΣV )
∝ LW (D|ΦW )× π(γji|θ)
∝ γ
δji1+δji2+θ
−1−1
ji exp
[
−rW (yji1, yji2)− θ
−1γji
]
.
Therefore, we sample γji from
Gamma
(
δji1 + δji2 + θ
−1, rW (yji1, yji2; γji = 1) + θ
−1
)
.
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B.1.5 Updating θ
Let ξ = 1/θ denote the precision parameter of frailty distribution. The full conditional
posterior distribution of ξ is given by
π(ξ|ΦW ,ΣV ) ∝ π(ξ)
J∏
j=1
nj∏
i=1
π(γji|ξ)
∝
ξnξ+bθ−1e−ξ(
∑J
j=1
∑nj
i=1 γji+aθ)
{Γ(ξ)}n
J∏
j=1
nj∏
i=1
γξ−1ji .
We revise the traditional random walk MH algorithm for updating ξ as done in Section
B.1.1 for βg. Let µξ(ξ) = ξ − min{0, D1,ξ(ξ)/D2,ξ(ξ)} and σ
2
ξ (ξ) = −c0/D2,ξ(ξ), where
D1,ξ(ξ) and D2,ξ(ξ) are the first and second gradients of log π(ξ|Φ
−(ξ)
W ,ΣV ) with respect to
ξ. A proposal ξ∗ is generated from the following Gamma distribution
Gamma
(
µξ(ξ
(t−1))2/σ2ξ (ξ
(t−1)), µ(ξ(t−1))/σ2ξ (ξ
(t−1))
)
.
The value of c0 > 0 is specified such that the algorithm achieve the desired acceptance rate.
The acceptance probability to update ξ is then given by
π(ξ∗|ΦW ,ΣV )Gamma
(
ξ∗|µξ(ξ
∗)2/σ2ξ (ξ
∗), µ(ξ∗)/σ2ξ (ξ
∗)
)
π(ξ(t−1)|ΦW ,ΣV )Gamma
(
ξ∗|µξ(ξ(t−1))2/σ
2
ξ (ξ
(t−1)), µ(ξ(t−1))/σ2ξ (ξ
(t−1))
) .
B.1.6 Updating Vj for Weibull-MVN model
The full conditional posterior distribution of Vj1 can be obtained by
π(Vj1|Φ
−(Vj1)
W , θ,ΣV ) ∝ LW (D|ΦW )× π(Vj|ΣV ).
∝ exp
{
nj∑
i=1
(
Vj1δji1 − γjiκw,1y
αw,1
ji1 ηji1
)
−
1
2
V ⊤j Σ
−1
V Vj
}
.
Analogously, the full conditionals of Vj2 and Vj3 can be written as
π(Vj2|Φ
−(Vj2)
W , θ,ΣV ) ∝ exp
{
nj∑
i=1
(
Vj2δji2(1− δji1)− γjiκw,2y
αw,2
ji1 ηji2
)
−
1
2
V ⊤j Σ
−1
V Vj
}
,
π(Vj3|Φ
−(Vj3)
W , θ,ΣV ) ∝ exp
{
nj∑
i=1
(
Vj3δji1δji2 − γjiκw,3(y
αw,3
ji2 − y
αw,3
ji1 )ηji3
)
−
1
2
V ⊤j Σ
−1
V Vj
}
.
As done in Section B.1.1, in a MH step for updating Vjg, we sample a proposal V
∗ from
a Normal distribution that is centered at µV (V
(t−1)
jg ) = V
(t−1)
jg −D1,V (V
(t−1)
jg )/D2,V (V
(t−1)
jg )
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and has a variance of σ2V (V
(t−1)) = −2.42/D2,V (V
(t−1)), where D1,V (Vjg) and D2,V (Vjg) are
the first and the second gradients of log π(Vjg|Φ
−(Vjg)
W , θ,ΣV ) with respect to Vjg. Finally,
the acceptance probability is given by
π(V ∗|Φ
−(Vjg)
W , θ,ΣV )Normal
(
V
(t−1)
jg |µV (V
∗), σ2V (V
∗)
)
π(V
(t−1)
jg |Φ
−(Vjg)
W , θ,ΣV )Normal
(
V ∗|µV (V
(t−1)
jg ), σ
2
V (V
(t−1)
jg )
) .
B.1.7 Updating ΣV for Weibull-MVN model
The full conditional posterior distribution of ΣV can be written as
π(ΣV |ΦW , θ) ∝ π(ΣV )
J∏
j=1
π(Vj|ΣV )
∝ |ΣV |
−J+ρv+4
2 exp
{
−
1
2
(
J∑
j=1
VjV
⊤
j + Ψv
)
Σ−1V
}
.
Therefore, we update ΣV from the following inverse-Wishart distribution:
ΣV |ΦW , θ ∼ inverse-Wishart
(
J∑
j=1
VjV
⊤
j +Ψv, J + ρv
)
.
B.1.8 Updating Vj and ΣV for Weibull-DPM model
Towards developing this model, suppose that, instead of arising from a single distribution,
the Vj are draws from a finite mixture of M multivariate Normal distributions, each with
their own mean vector and variance-covariance matrix, (µm, Σm) for m = 1, . . . ,M . Let
mj ∈ {1, . . . ,M} denote the specific component or class to which the j
th hospital be-
longs. Since the class-specific (µm, Σm) are not known they are taken to be draws from
some distribution, G0. Furthermore, since the ‘true’ class memberships are not known,
we denote the probability that the jth hospital belongs to any given class by the vector
p = (p1, . . . , pM) whose components add up to 1.0. In the absence of prior knowledge
regarding the distribution of class memberships for the J hospitals across the M classes, a
natural prior for p is the conjugate symmetric Dirichlet(τ/M, . . . , τ/M) distribution; the
hyperparameter, τ (Walker and Mallick, 1997). Jointly, this finite mixture distribution can
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be summarized by:
Vj|mj ∼ MVN(µmj ,Σmj ),
(µm,Σm) ∼ G0, for m = 1, . . . ,M,
mj |p ∼ Discrete(mj | p1, . . . , pM),
p ∼ Dirichlet(τ/M, . . . , τ/M), (7)
Finally, letting M → ∞ the resulting specification is referred to as a Dirichlet process
mixture of multivariate Normal distributions (DPM-MVN) (Ferguson, 1973; Bush and
MacEachern, 1996). When M → ∞, we cannot explicitly represent the infinite num-
ber of (µm, Σm). Instead, following Neal (2000), we represent and implement the MCMC
sampling for only those (µm, Σm) that are currently associated with some observations at
each iteration. In this subsection, we provide a step-by-step detailed description of the MH
algorithm to update Vj in Weibull-DPM model.
First, we update a class membership mj based onmj |m(−j),Vj, j = 1, · · · , J . Letm−(j)
denote a set of all class memberships from clusters except the cluster j. After identifying
the “nm” unique classes of m−(j), we compute the following probabilities for each of the
unique values m.
P (mj = m|m(−j),Vj) = b
n−j,m
J − 1 + τ
∫
Normal(Vj|µmj ,Σmj )dH−j,m(µ,Σ),(8)
P (mj 6= mk, ∀k 6= j |m(−j),Vj) = b
τ
J − 1 + τ
∫
Normal(Vj|µ,Σ)dG0(µ,Σ), (9)
where H−j,m is the posterior distribution of (µ,Σ) based on the prior G0 and {Vk : k 6=
j,mk = c}. The normalizing constant b makes “nm + 1” probabilities above sum to 1. Let
A = {j : mj = m} and HA be the posterior distribution of (µ, σ) based on the prior G0 and
{Vj : j ∈ A}. It can be shown that the HA is also Normal-inverse Wishart distribution as
G0 is conjugate to multivariate normal distribution:
1. we draw a sample of a class membership.
i) For each mj, identify the nm unique values of m(−j).
ii) For each of the unique values m, compute the following probabilities:
P (mj = m|m(−j),Vj) = b
n−j,m
J − 1 + τ
∫
Normal(Vj|µmj ,Σmj )dH−j,m(µ,Σ),
(10)
P (mj 6= mk, ∀k 6= j |m(−j),Vj) = b
τ
J − 1 + τ
∫
Normal(Vj|µ,Σ)dG0(µ,Σ), (11)
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where H−j,m is the posterior distribution of (µ,Σ) based on the prior G0 and {Vk :
k 6= j,mk = m}. The normalizing constant b makes nm + 1 probabilities above sum
to 1.0. Let A = {j : mj = m} and HA be the posterior distribution of (µ, σ) based on
the prior G0 and {Vj : j ∈ A}. It can be shown that the HA is also Normal-inverse
Wishart distribution as G0 is conjugate to multivariate normal distribution:
HA(µ,Σ|µA, ζA,ΨA, ρA),
where
µA =
1
ζ0
µ0 + |A|V¯A
1
ζ0
+ |A|
, ζA =
(
1
ζ0
+ |A|
)−1
, ρA = ρ0 + |A|,
ΨA = Ψ0 +
∑
j∈A
(
Vj − V¯A
) (
Vj − V¯A
)⊤
+
|A|
ζ0
1
ζ0
+ |A|
(
V¯A − µ0
) (
V¯A − µ0
)⊤
,(12)
with V¯A =
1
|A|
∑
k∈AVk. Now we define
Q(Vj , µ0, ζ0,Ψ0, ρ0)
=
∫
fN3(Vj|µ,Σ)dFNIW (µ,Σ|µ0, ζ0,Ψ0, ρ0)
=
|Ψ0|
ρ0
2∣∣∣∣Ψ0 + VjV ⊤j + 1ζ0µ0µ⊤0 −
(
1 + 1
ζ0
)−1 (
1
ζ0
µ0 + Vj
)(
1
ζ0
µ0 + Vj
)⊤∣∣∣∣
ρ0+1
2
×
1
(π
√
2(1 + ζ0))3
×
Γα,3(
ρ0+1
2
)
Γα,3(
ρ0
2
)
(13)
It follows that the integrals in (10) and (11) are equal to Q(Vj,µA, ζA,ΨA, ρA) and
Q(Vj ,µ0, ζ0,Ψ0, ρ0), respectively.
iii) Sample m
(new)
j based on the probabilities given in (10) and (11).
2. For all m ∈ {m1, . . . , mJ}, update (µm,Σm) using the posterior distribution that is
based on {Vj : j ∈ {k : mk = m}}.
3. For j = 1, . . . , J , update Vj using its full conditional using Metropolis-Hastings algo-
rithm.
4. We treat τ as random and assign gamma prior Gamma(aτ , bτ ) for τ . Following Escobar
and West (1995), we update τ by
i) sampling an c ∈ (0, 1) from Beta(τ + 1, J),
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ii) sampling the new τ from the mixture of two gamma distributions:
pcGamma(aτ + nm, bτ − log(c)) + (1− pc)Gamma(aτ + nm − 1, bτ − log(c)),
where the weight pc is defined such that pc/(1− pc) = (aτ + nm− 1)/{J(bτ − log(c))}.
5. Finally we calculate the total variance-covariance matrix:
ΣV =
1
J
J∑
j=1
{(
µmj − µ¯
)(
µmj − µ¯
)⊤
+ Σmj
}
, (14)
where µ¯ =
∑J
j=1µmj/J .
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B.2 PEM models
Let ΦP = {λ1,λ2,λ3,β1,β2,β3, ~γ, ~V } a set of parameters in the likelihood function of
PEM models. The observed data likelihood LP (D|ΦP ) is given by
J∏
j=1
nj∏
i=1
[
γjiηji1 exp
{
K1+1∑
k=1
λ1kI(s1,k−1 < yji1 ≤ s1,k)
}]δji1(1−δji2)
×
[
γ2jiηji1ηji3 exp
{
K1+1∑
k=1
λ1kI(s1,k−1 < yji1 ≤ s1,k) +
K3+1∑
k=1
λ3kI(s3,k−1 < yji2 ≤ s3,k)
}]δji1δji2
×
[
γjiηji2 exp
{
K2+1∑
k=1
λ2kI(s2,k−1 < yji2 ≤ s2,k)
}]δji2(1−δji1)
× exp {−rP (yji1, yji2)} , (15)
where ηjig = exp
(
x⊤jigβg + Vjg
)
and
rP (tji1, tji2)
=


γji
(
ηji1
∑K1+1
k=1 e
λ1,k∆1jik + ηji2
∑K2+1
k=1 e
λ2,k∆2jik + ηji3
∑K3+1
k=1 e
λ3,k∆∗3jik
)
, for Markov model
γji
(
ηji1
∑K1+1
k=1 e
λ1,k∆1jik + ηji2
∑K2+1
k=1 e
λ2,k∆2jik + ηji3
∑K3+1
k=1 e
λ3,k∆∗3jik
)
, for semi-Markov model
∆gjik = max
{
0,min(yji1, sg,k)− sg,k−1
}
,
∆∗gjil =


max
{
0,min(yji2, sg,l)−max(yji1, sg,l−1)
}
, for Markov model,
max
{
0,min(yji2 − yji1, sg,l)− sg,l−1)
}
, for semi-Markov model.
B.2.1 Reversible jump MCMC algorithm
For PEM models, we use a random scan Gibbs sampling scheme, randomly selecting and
updating a (vector of) model parameter at each iteration. Let BIg and DIg denote a birth
and a death of a new time split for transition g ∈ {1, 2, 3}. The probabilities for the update
BIg and DIg are given by
π
Kg
BIg
= ρgmin
{
1,
Poisson(Kg + 1|αKg)
Poisson(Kg|αKg)
}
= ρgmin
{
1,
αKg
Kg + 1
}
,
π
Kg
DIg
= ρgmin
{
1,
Poisson(Kg − 1|αKg)
Poisson(Kg|αKg)
}
= ρgmin
{
1,
Kg
αKg
}
,
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where ρg is set such that π
Kg
BIg
+ π
Kg
DIg
< Cg and
∑3
g=1Cg < 1 for Kg = 1, . . . , Kg,max.
Kg,max is the preassigned upper limit on the number of time splits for transition g and we
set π
Kg,max
BIg
= 0. The probabilities of updating other parameters are equally specified from
remaining probability 1−
∑3
g=1(π
Kg
BIg
+ π
Kg
DIg
).
B.2.2 Updating βg
The full conditional posterior distribution of β1 can be obtained by
π(β1|Φ
−(β1)
P ,µλ,σ
2
λ, θ,ΣV )
∝ LP (D|ΦP )
∝
J∏
j=1
nj∏
i=1
exp
(
δji1x
⊤
ji1β1 − γjie
x⊤ji1β1+Vj1
K1+1∑
k=1
eλ1,k∆1jik
)
,
where µλ = (µλ1 , µλ2, µλ3)
⊤ and σ2λ = (σ
2
λ1
, σ2λ2 , σ
2
λ3
)⊤. Analogously, the full conditionals of
β2 and β3 are given by
π(β2|Φ
−(β2)
P ,µλ,σ
2
λ, θ,ΣV )
∝
J∏
j=1
nj∏
i=1
exp
{
δji2(1− δji1)x
⊤
ji2β2 − γjie
x⊤ji2β2+Vj2
K2+1∑
l=1
eλ2,l∆2jil
}
,
π(β3|Φ
−(β3)
P ,µλ,σ
2
λ, θ,ΣV )
∝
J∏
j=1
nj∏
i=1
exp
(
δji1δji2x
⊤
ji3β3 − γjie
x⊤ji3β3+Vj3
K3+1∑
m=1
eλ3,m∆∗3jim
)
.
As the full conditionals do not have standard forms, we use MH algorithm to update
each element of βg. A detailed description of the adapted random walk MH algorithm is
provided in Section B.1.1.
B.2.3 Updating λg
The full conditional posterior distribution of λ1 is given by
π(λ1|Φ
−(λ1)
P ,µλ,σ
2
λ, θ,ΣV )
∝ LP (D|ΦP )π(λ1|µλ1 , σ
2
λ1
)
∝
J∏
j=1
nj∏
i=1
exp
{
δji1λ1kI(s1,k−1 < yji1 ≤ s1,k)− γji∆
1
jike
λ1kηji1
}
× exp
{
−
1
2σ2λ1
(λ1 − µλ11)
⊤Σ−1λ1 (λ1 − µλ11
}
,
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where 1 denotes a Kg + 1 dimensional vector of 1’s. Analogously, the full conditionals of
λ2 and λ3 are given by
π(λ2|Φ
−(λ2)
P ,µλ,σ
2
λ, θ,ΣV )
∝
J∏
j=1
nj∏
i=1
exp
{
δji2(1− δji1)λ2kI(s2,k−1 < yji2 ≤ s2,k)− γji∆
2
jike
λ2kηji2
}
× exp
{
−
1
2σ2λ2
(λ2 − µλ21)
⊤Σ−1λ2 (λ2 − µλ21)
}
,
π(λ3|Φ
−(λ3)
P ,µλ,σ
2
λ, θ,ΣV )
∝
J∏
j=1
nj∏
i=1
exp
{
δji1δji2λ3kI(s3,k−1 < yji2 ≤ s3,k)− γji∆
∗3
jike
λ3kηji3
}
× exp
{
−
1
2σ2λ3
(λ3 − µλ31)
⊤Σ−1λ3 (λ3 − µλ31)
}
,
Since the full conditionals do not follow known distributions, MH algorithm is used to
update each element of λg. We follow the adapted random walk MH algorithm described
in Section B.1.1.
B.2.4 Updating γji
The full conditional posterior distribution of γji is given by
π(γji|Φ
−(γji)
P ,µλ,σ
2
λ, θ,ΣV )
∝ LP (D|ΦP )× π(γji|θ)
∝ γ
δji1+δji2+θ−1−1
ji exp
[
−rP (yji1, yji2)− θ
−1γji
]
.
Therefore, we sample γji from
Gamma
(
δji1 + δji2 + θ
−1, rP (yji1, yji2; γji = 1) + θ
−1
)
.
B.2.5 Updating (µg, σ
2
g)
Full conditional posterior distributions for µλg and υg = 1/σ
2
λg
, g = 1, 2, 3 are Normal
and Gamma distribution, respectively. Therefore, we use Gibbs sampling to update the
parameters. We obtain the posterior samples of µλg from
Normal
(
1⊤Σ−1λg λg
1⊤Σ−1λg 1
,
σ2λg
1⊤Σ−1λg 1
)
,
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because the full conditional is given by
π(µλg |ΦP ,µ
−(µλg )
λ ,σ
2
λ, θ,ΣV ) ∝ π(λg|µλg , σ
2
λg
)π(µλg)
∝ exp

1
⊤Σ−1λg 1
2σ2λg
(
µλg −
1⊤Σ−1λg λg
1⊤Σ−1λg 1
)2
 .
We update υg = 1/σ
−2
λg
from a Gamma distribution given by
Gamma
(
aσ,g +
Kg + 1
2
, bσ,g +
1
2
(µλg1− λg)
⊤Σ−1λg (µλg1− λg)
)
,
as the full conditional of υg is
π(υg|ΦP ,µλ, (σ
2
λ)
−(σ2
λg
)
, θ,ΣV )
∝ π(λg|µλg , σ
2
λg
)π(υg)
∝ (υg)
aσ,g+
Kg+1
2
−1 exp
[
−
{
bσ,g +
1
2
(µλg1− λg)
⊤Σ−1λg (µλg1− λg)
}
υg
]
.
B.2.6 Updating θ
Updating the precision parameter ξ = 1/θ in PEM models requires the exactly same step
as that in Weibull models. Therefore, the readers are referred to Section B.1.5 for the full
conditional posterior distribution of ξ and the MH algorithm.
B.2.7 Updating Vj for PEM-MVN model
The full conditional posterior distribution of Vj1 can be obtained by
π(Vj1|Φ
−(Vj1)
P ,µλ,σ
2
λ, θ,ΣV ) ∝ LP (D|ΦP )× π(Vj|ΣV ).
∝ exp
{
nj∑
i=1
(
Vj1δji1 − γjiηji1
K1+1∑
k=1
eλ1,k∆1jik
)
−
1
2
V ⊤j Σ
−1
V Vj
}
.
Analogously, the full conditionals of Vj2 and Vj3 can be written as
π(Vj2|Φ
−(Vj2)
P ,µλ,σ
2
λ, θ,ΣV ) ∝ exp
{
nj∑
i=1
(
Vj2δji2(1− δji1)− γjiηji2
K2+1∑
l=1
eλ2,l∆2jil
)
−
1
2
V ⊤j Σ
−1
V Vj
}
,
π(Vj3|Φ
−(Vj3)
P ,µλ,σ
2
λ, θ,ΣV ) ∝ exp
{
nj∑
i=1
(
Vj3δji1δji2 − γjiηji3
K3+1∑
m=1
eλ3,m∆∗3jim
)
−
1
2
V ⊤j Σ
−1
V Vj
}
.
For updating each element of Vj, we use the adapted random walk MH algorithm provided
in Section B.1.6.
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B.2.8 Updating ΣV for PEM-MVN model
The full conditional posterior distribution of ΣV in PEM-MVN model is the exactly same as
that in Weibull-MVN model. Readers are referred to Section B.1.7 for the Gibbs sampling
step for updating ΣV .
B.2.9 Updating Vj and ΣV for PEM-DPM model
Updating Vj and ΣV in PEM-DPM requires the exactly same step as that in Weibull-DPM.
Therefore, the readers are referred to Section B.1.8 for detailed algorithm to update Vj and
ΣV . Note that in step 3 of the algorithm, the full conditional of Vj needs to be obtained
based on LP (D|ΦP ) for PEM-DPM.
B.2.10 Update BI
We specify log h0(t) =
∑Kg+1
k=1 λg,kI(t ∈ Ig,k) for the baseline hazard function corresponding
to transition g with partition (Kg, sg). Updating (Kg, sg) requires generating a proposal
partition and then deciding whether or not to accept the proposal. For update BI (a birth
move), we first select a proposal split time s∗ uniformly from among the observed event
times which are not included in the current partition. Suppose s∗ lies between the (k−1)th
and kth split times in the current partition. The proposal partition is then defined as
(0 = sg,0, ..., sg,k−1, s
∗, sg,k, ..., sg,K1+1 = sg,max)
≡ (0 = s∗g,0, ..., s
∗
g,k−1, s
∗
g,k, s
∗
g,k+1, ..., s
∗
g,K1+2
= sg,max).
A height of the two new intervals created by the split at time s∗ also needs to be proposed.
In order to make the old height be a compromise of the two new heights, the former is
taken to be the weighted mean of the latter on the log scale:
(s∗ − sg,k−1)λ
∗
g,k + (sg,k − s
∗)λ∗g,k+1 = (sg,k − sg,k−1)λg,k.
Defining the multiplicative perturbation exp(λ∗g,j+1)/ exp(λ
∗
g,j) = (1 − U)/U , where U ∼
Uniform(0, 1), the new heights are given by
λ∗g,k = λg,k −
sg,k − s
∗
sg,k − sg,k−1
log
(
1− U
U
)
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and
λ∗g,k+1 = λg,k +
s∗ − sg,k−1
sg,k − sg,k−1
log
(
1− U
U
)
.
The acceptance probability in the Metropolis-Hastings-Green step can be written as the
product of the likelihood ratio, prior ratio, proposal ratio, and Jacobian. For g = 1, they
are given by
likelihood ratio =
LP (D|Φ
∗
P )
LP (D|ΦP )
,
prior ratio =
Poisson(K1 + 1|αK1)×MVNK1+2(λ
∗
1|µλ11, σ
2
λ1
Σ∗λ1)
Poisson(K1|αK1)×MVNK1+1(λ1|µλ11, σ
2
λ1
Σλ1)
×
(2K1 + 3)(2K1 + 2)(s
∗ − s1,k−1)(s1,k − s
∗)
s21,max(s1,k − s1,k−1)
,
proposal ratio =
πDI × (1/(K1 + 1))
πBI × (1/♯{yji1 : δji1 = 1})× Uniform(U |0, 1)
=
ρmin(1, (K1 + 1)/αK1)♯{yji1 : δji1 = 1}
ρmin(1, αK1/(1 +K1))(K1 + 1)
=
♯{yji1 : δji1 = 1}
αK1
,
Jacobian =
∣∣∣∣∣∣
dλ∗1,k/dλ1,k dλ
∗
1,k/dU
dλ∗1,k+1/dλ1,k dλ
∗
1,k+1/dU
∣∣∣∣∣∣ =
1
U(1− U)
, (16)
where Φ∗P is ΦP with λ1 replaced by λ
∗
1.
B.2.11 Update DI
For update DI (a death or reverse move), we first sample one of the Kg split times, sg,k.
The proposal for time splits is given by
(0 = sg,0, ..., sg,k−1, sg,k+1, ..., sg,Kg+1 = sg,max)
≡ (0 = s∗g,0, ..., s
∗
g,k−1, s
∗
g,k, ..., s
∗
g,Kg
= sg,max).
Following Green (1995):
(sg,k − sg,k−1)λg,k + (sg,k+1 − sg,k)λg,k+1 = (sg,k+1 − sg,k−1)λ
∗
g,k,
perturbation :
eλg,k+1
eλg,k
=
1− U∗
U∗
,
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where U ∼ Uniform(0, 1). Then the acceptance probability can be obtained as the product
of following four components (for g = 1):
likelihood ratio =
LP (D|Φ
∗
P )
LP (D|ΦP )
,
prior ratio =
Poisson(K1 − 1|αK1)×MVNK1(λ
∗
1|µλ11, σ
2
λ1
Σ∗λ1)
Poisson(K1|αK1)×MVNK1+1(λ1|µλ11, σ
2
λ1
Σλ1)
×
s21,max(s1,k+1 − s1,k−1)
(2K1 + 1)2K1(s1,k − s1,k−1)(s1,k+1 − s1,k)
,
proposal ratio =
πBI × (1/♯{yji1 : δji1 = 1})
πDI × (1/K1)
=
ρmin(1, αK1/K1)K1
ρmin(1, K1/αK1)♯{yji1 : δji1 = 1}
=
αK1
♯{yji1 : δji1 = 1}
,
Jacobian =
∣∣∣∣∣∣
dλ1k/dλ
∗
1k dλ1k/dλ
∗
1,k+1
dU/dλ∗1k dU/dλ
∗
1,k+1
∣∣∣∣∣∣ = U(1 − U).
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C The potential use of existing methods
The methods in the main manuscript were developed specifically for on-going collaboration
examining the risk of readmission following a diagnosis of pancreatic cancer. As indicated
in the manuscript, the current standard for the analysis of cluster-correlated readmission
data is a logisitic-Normal generalized linear mixed model. This model ignores death as a
competing risk, however, and, as such, is inappropriate in for the study of pancreatic cancer
due to its strong force of mortality.
Viewing the data arising in the pancreatic cancer as cluster-correlated semi-competing
risks data, the existing literature does have a number of options that could be considered.
Here we review two of these options, specifically those proposed in Liquet et al. (2012) and
Gorfine and Hsu (2011). For the former, we note that the methods have been implemented
in the frailtypack package for R.
For convenience, expressions (4)-(6) from the main manuscript that the describe the
key features of the proposed hierarchical model are repeated here:
h1(tji1; γji,Xji1, Vj1) = γji h01(tji1) exp{X
T
ji1β1 + Vj1}, tji1 > 0
h2(tji2; γji,Xji2, Vj2) = γji h02(tji2) exp{X
T
ji2β2 + Vj2}, tji2 > 0
h3(tji2|tji1; γji,Xji3, Vj3) = γji h03(tji2|tji1) exp{X
T
ji3β3 + Vj3}, tji2 > tji1,
C.1 Liquet et al. (2012)
The R package frailtypack provides several classes of frailty models for multivariate
survival data including shared frailty models, additive frailty models, nested frailty models,
joint frailty models (Rondeau et al., 2012). Among these, the shared frailty model and the
joint frailty model are most relevant the context we consider; additionally, these models
form the basis for the analyses presented in Liquet et al. (2012). Here we provide a summary
of these two classes using the notation developed in the manuscript, as well as an overview
of their drawbacks in regard to the analysis of cluster-correlated semi-competing risks data.
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C.1.1 The shared frailty model
In the shared frailty model, the hazard function for the subject i in the cluster j conditional
on the cluster-specific shared frailty term ηj = (ηj1, ηj2, ηj3) is given by
h1(tji1;Xji1, ηj1) = ηj1h01(tji1) exp{X
T
ji1β1}, tji1 > 0
h2(tji2;Xji2, ηj2) = ηj2h02(tji2) exp{X
T
ji2β2}, tji2 > 0
h3(tji2|tji1;Xji3, ηj3) = ηj3h03(tji2 − tji1) exp{X
T
ji3β3}, tji2 > tji1, (17)
Key features of this model, in relation to the proposed framework are:
• Cluster-specific effects are represented via the (ηj1, ηj2, ηj3), each of which is assigned
an independent univariate parametric distribution (either a log-Normal or a Gamma).
As such, the model does not permit the characterization of covariation between the
cluster-specific random effects. In contrast, the proposed methods provides analysts
with two choices for the joint distribution of the Vj’s: a parametric MVN or a non-
parametric DPM-MVN.
• There is no patient-specific term, analogous to the γji in the proposed model. As
such a potentially important source of within-subject correlation between T1 and T2
is not accounted for.
• Similar to the propose methods, however, is that the baseline hazard function for
h3() can be specified non-parametrically (via a spline) or parametrically (using the
Weibull distribution).
• Although not evident from the model specification, estimation of the shared frailty
model is based on three separate fits of the three models. In contrast, because the
proposed model considers several components of covariation (i.e. covariation among
the Vj’s and the patient-specific γji’s) we perform estimation/inference using single
likelihood. Indeed for the shared frailty model to accommodate these components of
covariation, a completely new framework for estimation/inference would need to be
developed.
• Estimation of the (ηj1, ηj2, ηj3) proceeds using empirical Bayes (after estimation of the
remaining components via an integrated likelihood). Uncertainty for these estimates
are only available when their distributions are taken to be Gamma distributions.
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C.1.2 The joint frailty model
Two variations of a joint frailty model have been implemented in the frailtypack package.
The first was developed for the analysis of a recurrent non-terminal event and a terminal
event and specifies a single hazard function for each. Specifically, the model is given by:
h1(tki1|ωi) = ωir0(tki1) exp{X
T
i1β1}, for recurrent non-terminal event
h2(ti2|ωi) = ω
α
i h0(ti2) exp{X
T
i2β2}, for the terminal event
ωi ∼ Gamma(1/θ, 1/θ). (18)
where ωi is a common subject-specific frailty representing unobserved covariates that impact
both events. We note that this is specification is similar to the model proposed by Liu et al.
(2004).
The second joint frailty model implemented in the frailtypack package is for model-
ing two clustered survival outcomes. Specifically, the model posits that the event-specific
hazard functions for the jth cluster are structured as follows:
h(tji1|ηj) = h01(tji1) exp{X
T
ji1β1 + ηj}, for any event
h(tji2|ηj) = h02(tji2) exp{X
T
ji2β2 + αηj}, for the terminal event
ηj ∼ Normal(0, σ
2) (19)
In relation to the context we consider, the central limitation of these model is that they
only consider a single level of the two-level hierarchy inherent to cluster-correlated semi-
competing risks data. Specifically, as applied and described in the fraitypack package,
the first model only considers patient-specific effects while the second model only considers
cluster-specific effects. As such neither model would be appropriate for our motivating
application since (i) ignoring cluster-specific effects means that one cannot address several
of our key scientific questions and (ii) ignoring patient-level effects can result in substantial
bias (see the simulation studies in Section 5 of the main manuscript).
We also note that a second limitation is that model (19) does not consider the transition
from the non-terminal event to the terminal event; that is there is no analogue for h3() in
the model. This represents a limitation in the sense that information readily available in
the data is ignored. In the motivating application in the main manuscript, for example, the
fact that the time of death following readmission within 90 days is known for 608 (11.5%)
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patients is ignored. Finally, although model (18) does permit a patient to transition from
the non-terminal state to the terminal state, this transition is assumed to occur at the
same rate at which a patient who is in the initial state transitions directly into the terminal
state; that is, in contrast to the proposed model that distinguishes h2() from h3(), model
(18) only has a single hazard for the terminal event.
C.2 Gorfine and Hsu (2011)
Gorfine and Hsu (2011) explicitly consider the related but distinct problem of analyzing
cluster correlated competing risk data for which T1 and T2 are both terminal events (i.e.
death due to two causes). Towards analyzing such data, they propose the following hierar-
chical model:
h(tji1|Xji, ǫj1(tji1)) = h01(tji1) exp{X
T
jiβ1 + ǫj1(tji1)}, for cause 1
h(tji2|Xji, ǫj2(tji2)) = h02(tji2) exp{X
T
jiβ2 + ǫj2(tji2)}, for cause 2 (20)
to describe the risk of transitioning into one of the two terminal states for the ith patient in
the jth cluster. As part of their development, Gorfine and Hsu (2011) provide a framework
within which the distribution of the cluster-specific ǫjg(t) terms can be flexibly specified.
While this flexibility is very appealing, direct application of this model to our motivating
application would be subject to a number of limitations mainly because the method was
not designed for the cluster-correlated semi-competing risks setting. Specifically,
• Similar to the joint frailty model given by (19), the application of model (20) means
that one would ignore information in the data on the transition from the non-terminal
event to the terminal event; that is, there is not analogue of h3().
• Although model (20) includes cluster-specific random effects, it does not include
specification of patient-specific terms analogous to γji in the proposed model. As is
clear from the simulations presented in Section 5 of the main manuscript, ignoring this
component of variation can lead to substantial bias in estimation and poor inferential
properties in the cluster-correlated semi-competing risks setting.
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D Simulation Results
In order to supplement the results from simulation studies, we provide estimated percent
bias, coverage probability, and average relative width of 95% credible/confidence inter-
vals for β1, β2, β3, and θ for our four proposed models and four types of SF models of
Liquet et al. (2012) in Table D.1-D.6. We also provide estimated transition-specific base-
line survival functions for the models under simulation scenarios 2,3, and 5 in Figure D.1.
Note that since results from SF models are almost identical between models that adopt
the independent gamma distributions for cluster-specific random effects and those that
adopt the independent log-Normal distributions, we only present the results from SF mod-
els with the gamma cluster-specific random effects in Figure D.1. We also present Table
D.7 that augments Table 6 in the main manuscript by additionally presenting results for
the Liquet et al. (2012)’s models that adopt independent log-Normal distributions for the
cluster-specific random effects.
The results presented in this section are generally consistent with the conclusions we
drew in the main paper: contrary to the existing SF models, our proposed models yielded a
small bias and coverage probability estimated to be close to the nominal 0.95 for regression
parameters and θ (except scenario 4 for which θ=0); all four of the proposed models estimate
the three baseline survival functions very well.
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Table D.1: Estimated percent bias and coverage probability for β1 and θ for six analyses described in Section 5.2, across six
simulation scenarios given in Table 3. Throughout values are based on results from R=500 simulated datasets.
Percent Bias Coverage Probability
Scenario True Weibull Weibull Weibull Weibull PEM PEM Spline Spline Weibull Weibull Weibull Weibull PEM PEM Spline Spline
value -MVN -DPM -SFG
a -SFLN
b -MVN -DPM -SFG -SFLN -MVN -DPM -SFG -SFLN -MVN -DPM -SFG -SFLN
β11 0.50 0.1 0.2 -19.8 -21.3 0.4 0.4 -21.0 -20.8 0.96 0.96 0.01 0.01 0.95 0.96 0.00 0.00
1 β12 0.80 0.2 0.3 -19.7 -21.3 0.5 0.4 -21.0 -20.8 0.95 0.95 0.00 0.00 0.96 0.97 0.00 0.00
β13 -0.50 0.3 0.3 -19.8 -18.8 0.3 0.3 -21.2 -20.9 0.97 0.96 0.31 0.31 0.96 0.96 0.25 0.26
θ 0.50 1.0 1.3 1.4 1.2 0.95 0.95 0.93 0.94
β11 0.50 -0.1 -0.0 -31.8 -33.4 0.1 0.1 -32.8 -32.8 0.94 0.94 0.00 0.00 0.94 0.93 0.00 0.00
2 β12 0.80 0.1 0.2 -31.7 -33.3 0.4 0.3 -32.7 -32.7 0.97 0.97 0.00 0.00 0.94 0.95 0.00 0.00
β13 -0.50 1.2 1.3 -31.1 -29.2 1.1 1.1 -32.2 -32.2 0.94 0.95 0.05 0.05 0.94 0.94 0.04 0.04
θ 1.00 0.4 0.7 0.7 0.6 0.94 0.95 0.94 0.95
β11 0.50 0.3 0.3 -19.9 -20.7 0.7 0.7 -21.0 -20.9 0.94 0.94 0.00 0.00 0.93 0.94 0.00 0.00
3 β12 0.80 0.4 0.4 -19.8 -20.7 0.8 0.8 -20.9 -20.8 0.94 0.94 0.00 0.00 0.94 0.94 0.00 0.00
β13 -0.50 0.4 0.3 -20.1 -19.7 0.5 0.6 -21.2 -21.2 0.96 0.96 0.31 0.29 0.95 0.96 0.27 0.27
θ 0.50 2.0 2.1 3.2 3.2 0.96 0.96 0.93 0.95
β11 0.50 3.7 3.7 0.2 -2.9 4.7 4.6 0.3 0.6 0.87 0.86 0.96 0.91 0.81 0.83 0.96 0.95
4 β12 0.80 3.6 3.6 -0.0 -3.1 4.5 4.5 0.1 0.4 0.80 0.79 0.95 0.89 0.69 0.70 0.95 0.95
β13 -0.50 4.0 4.0 0.2 7.3 4.8 4.7 0.2 0.6 0.93 0.94 0.94 0.88 0.93 0.93 0.93 0.94
θ 0.00
β11 0.50 -0.3 0.1 -20.3 -24.6 0.0 0.3 -21.1 -20.9 0.94 0.95 0.00 0.00 0.96 0.96 0.00 0.00
5 β12 0.80 0.0 0.3 -20.0 -24.6 0.3 0.6 -20.9 -20.7 0.95 0.95 0.00 0.00 0.96 0.96 0.00 0.00
β13 -0.50 -0.2 0.2 -20.4 -13.7 -0.2 0.2 -21.3 -21.1 0.94 0.94 0.29 0.26 0.94 0.94 0.25 0.26
θ 0.50 -0.2 1.0 0.4 1.3 0.95 0.95 0.95 0.96
β11 0.50 9.3 9.4 -22.1 -23.6 0.4 0.3 -25.9 -25.1 0.58 0.57 0.00 0.00 0.94 0.94 0.00 0.00
6 β12 0.80 9.7 9.8 -22.0 -23.5 0.5 0.5 -25.8 -25.0 0.20 0.20 0.00 0.00 0.94 0.95 0.00 0.00
β13 -0.50 10.2 10.2 -21.6 -18.2 0.8 0.7 -26.1 -24.9 0.81 0.80 0.21 0.21 0.93 0.94 0.10 0.10
θ 0.50 52.8 53.0 1.8 1.7 0.00 0.00 0.95 0.96
a The SF models that adopt the independent gamma distributions for cluster-specific random effects
b The SF models that adopt the independent log-Normal distributions for cluster-specific random effects
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Table D.2: Estimated percent bias and coverage probability for β2 for six analyses described in Section 5.2, across six simulation
scenarios given in Table 3. Throughout values are based on results from R=500 simulated datasets.
Percent Bias Coverage Probability
Scenario True Weibull Weibull Weibull Weibull PEM PEM Spline Spline Weibull Weibull Weibull Weibull PEM PEM Spline Spline
value -MVN -DPM -SFG
a -SFLN
b -MVN -DPM -SFG -SFLN -MVN -DPM -SFG -SFLN -MVN -DPM -SFG -SFLN
β21 0.50 -0.1 -0.0 -27.9 -25.9 -0.2 -0.3 -26.1 -26.1 0.93 0.93 0.00 0.00 0.94 0.94 0.00 0.00
1 β22 0.80 0.3 0.4 -27.9 -25.6 0.2 0.1 -25.8 -25.7 0.96 0.96 0.00 0.00 0.96 0.96 0.00 0.00
β23 -0.50 1.3 1.4 -26.5 -21.1 0.9 0.9 -25.2 -25.1 0.94 0.93 0.34 0.35 0.95 0.95 0.34 0.34
β21 0.50 -0.1 0.1 -39.2 -39.2 -0.2 -0.2 -39.9 -39.8 0.96 0.96 0.00 0.00 0.96 0.96 0.00 0.00
2 β22 0.80 0.2 0.3 -39.1 -39.0 0.0 0.0 -39.6 -39.6 0.96 0.97 0.00 0.00 0.96 0.97 0.00 0.00
β23 -0.50 1.3 1.4 -38.5 -38.3 0.8 0.8 -39.2 -39.2 0.93 0.94 0.07 0.07 0.93 0.93 0.06 0.06
β21 0.50 0.3 0.3 -27.4 -24.9 0.3 0.3 -25.7 -25.6 0.95 0.95 0.01 0.01 0.95 0.96 0.00 0.00
3 β22 0.80 0.5 0.5 -27.5 -24.8 0.5 0.5 -25.5 -25.4 0.95 0.95 0.00 0.00 0.94 0.95 0.00 0.00
β23 -0.50 2.5 2.5 -24.9 -23.2 2.3 2.5 -24.2 -24.1 0.95 0.95 0.37 0.38 0.94 0.94 0.35 0.36
β21 0.50 4.5 4.5 -4.9 -4.4 4.7 4.7 -0.6 -0.6 0.89 0.89 0.91 0.90 0.87 0.88 0.96 0.96
4 β22 0.80 4.6 4.6 -5.2 -4.6 4.8 4.8 -0.6 -0.5 0.78 0.78 0.88 0.88 0.76 0.79 0.92 0.92
β23 -0.50 5.4 5.4 25.8 18.1 5.4 5.5 -0.1 -0.0 0.92 0.92 0.88 0.88 0.91 0.93 0.93 0.92
β21 0.50 -0.3 0.2 -26.6 -25.1 -0.4 -0.0 -26.1 -25.8 0.94 0.95 0.00 0.00 0.94 0.95 0.00 0.00
5 β22 0.80 -0.4 0.1 -26.8 -25.3 -0.5 -0.1 -26.2 -25.9 0.96 0.96 0.00 0.00 0.96 0.96 0.00 0.00
β23 -0.50 0.1 0.5 -27.2 -24.9 -0.4 0.1 -26.1 -25.8 0.95 0.95 0.33 0.35 0.95 0.95 0.30 0.31
β21 0.50 9.2 9.3 -25.1 -23.8 0.1 0.1 -25.0 -25.0 0.70 0.70 0.01 0.01 0.95 0.95 0.00 0.01
6 β22 0.80 9.7 9.7 -25.4 -23.8 0.4 0.3 -24.8 -24.8 0.40 0.39 0.00 0.00 0.94 0.95 0.00 0.00
β23 -0.50 10.4 10.4 -26.6 -13.6 0.8 0.8 -24.5 -24.5 0.85 0.85 0.47 0.47 0.94 0.95 0.36 0.35
a The SF models that adopt the independent gamma distributions for cluster-specific random effects
b The SF models that adopt the independent log-Normal distributions for cluster-specific random effects
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Table D.3: Estimated percent bias and coverage probability for β3 for six analyses described in Section 5.2, across six simulation
scenarios given in Table 3. Throughout values are based on results from R=500 simulated datasets.
Percent Bias Coverage Probability
Scenario True Weibull Weibull Weibull Weibull PEM PEM Spline Spline Weibull Weibull Weibull Weibull PEM PEM Spline Spline
value -MVN -DPM -SFG
a -SFLN
b -MVN -DPM -SFG -SFLN -MVN -DPM -SFG -SFLN -MVN -DPM -SFG -SFLN
β31 1.00 0.4 0.5 -21.8 -12.5 0.7 0.8 -13.3 -13.2 0.94 0.94 0.08 0.09 0.94 0.94 0.06 0.06
1 β32 1.00 0.2 0.3 -20.5 -9.0 0.6 0.6 -9.7 -9.7 0.96 0.96 0.28 0.32 0.93 0.94 0.27 0.28
β33 -1.00 0.2 0.3 44.3 -12.5 0.4 0.4 -13.4 -13.3 0.94 0.94 0.47 0.53 0.94 0.94 0.49 0.50
β31 1.00 0.1 0.3 -24.1 -25.3 0.6 0.6 -24.8 -24.7 0.95 0.95 0.00 0.00 0.95 0.95 0.00 0.00
2 β32 1.00 0.4 0.5 -22.8 -24.1 0.8 0.8 -23.3 -23.3 0.94 0.94 0.00 0.00 0.95 0.95 0.00 0.00
β33 -1.00 0.2 0.4 -23.8 -22.6 0.4 0.4 -24.6 -24.5 0.96 0.96 0.08 0.07 0.95 0.95 0.06 0.07
β31 1.00 0.6 0.6 -21.4 -14.4 1.1 1.1 -12.6 -12.5 0.96 0.96 0.10 0.14 0.95 0.95 0.09 0.09
3 β32 1.00 0.7 0.8 -19.2 -11.2 1.2 1.2 -9.0 -8.9 0.95 0.95 0.35 0.40 0.94 0.94 0.37 0.38
β33 -1.00 0.3 0.3 13.1 -10.1 0.5 0.6 -12.6 -12.5 0.95 0.95 0.52 0.57 0.93 0.94 0.54 0.54
β31 1.00 3.4 3.4 -0.6 11.9 4.1 3.9 11.0 11.3 0.87 0.88 0.11 0.12 0.84 0.86 0.15 0.15
4 β32 1.00 3.4 3.5 5.6 19.2 4.2 4.0 18.3 18.6 0.88 0.88 0.00 0.00 0.83 0.86 0.00 0.00
β33 -1.00 3.0 3.0 20.6 11.6 3.3 3.5 10.3 10.7 0.95 0.95 0.51 0.57 0.94 0.94 0.62 0.61
β31 1.00 -0.0 0.5 -22.4 -16.0 0.4 0.8 -14.2 -14.0 0.97 0.96 0.05 0.07 0.96 0.97 0.04 0.05
5 β32 1.00 0.0 0.6 -20.2 -12.4 0.4 0.9 -10.4 -10.1 0.96 0.95 0.27 0.31 0.95 0.95 0.25 0.26
β33 -1.00 0.0 0.5 36.3 -11.4 0.3 0.6 -14.1 -13.9 0.94 0.94 0.44 0.49 0.95 0.94 0.46 0.47
β31 1.00 8.4 8.5 -28.5 -28.5 0.5 0.5 -30.4 -30.3 0.31 0.30 0.00 0.00 0.96 0.95 0.00 0.00
6 β32 1.00 8.9 9.0 -20.3 -20.3 0.6 0.6 -22.0 -21.8 0.28 0.27 0.00 0.00 0.95 0.95 0.00 0.00
β33 -1.00 8.8 8.9 -27.9 -27.8 0.4 0.4 -30.2 -30.1 0.67 0.67 0.00 0.00 0.95 0.95 0.00 0.00
a The SF models that adopt the independent gamma distributions for cluster-specific random effects
b The SF models that adopt the independent log-Normal distributions for cluster-specific random effects
26
Time
Ba
se
lin
e 
su
rv
iva
l f
un
ct
io
n
0.
0
0.
5
1.
0
0 30 60 90
Scenario 2: S01(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time
0.
0
0.
5
1.
0
0 30 60 90
Scenario 2: S02(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time since nonterminal event
0.
0
0.
5
1.
0
0 30 60 90
Scenario 2: S03(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time
Ba
se
lin
e 
su
rv
iva
l f
un
ct
io
n
0.
0
0.
5
1.
0
0 30 60 90
Scenario 3: S01(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time
0.
0
0.
5
1.
0
0 30 60 90
Scenario 3: S02(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time since nonterminal event
0.
0
0.
5
1.
0
0 30 60 90
Scenario 3: S03(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time
Ba
se
lin
e 
su
rv
iva
l f
un
ct
io
n
0.
0
0.
5
1.
0
0 30 60 90
Scenario 5: S01(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time
0.
0
0.
5
1.
0
0 30 60 90
Scenario 5: S02(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Time since nonterminal event
0.
0
0.
5
1.
0
0 30 60 90
Scenario 5: S03(t)
Truth
Weibull−MVN
Weibull−DPM
Weibull−SF
PEM−MVN
PEM−DPM
Spline−SF
Figure D.1: Estimated transition-specific baseline survival functions, S0g(·)=exp(−H0g(·)),
for each six analyses described in Section 5 under simulation scenarios 2, 3 and 5.
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Table D.4: Average relative width of 95% credible/confidence intervals for β1 and θ, with
the Weibull-MVN model taken as the referent, across six simulation scenarios given in
Table 3. Throughout values are based on results from R=500 simulated datasets.
Scenario Weibull Weibull Weibull Weibull PEM PEM Spline Spline
-MVN -DPM -SFG
a -SFLN
b -MVN -DPM -SFG -SFLN
β11 1.00 1.00 0.81 0.78 1.02 1.02 0.81 0.81
1 β12 1.00 1.00 0.77 0.74 1.04 1.04 0.77 0.77
β13 1.00 1.00 0.84 0.81 1.00 1.01 0.83 0.84
θ 1.00 1.00 1.10 1.12
β11 1.00 1.00 0.73 0.70 1.02 1.02 0.73 0.73
2 β12 1.00 1.00 0.69 0.66 1.03 1.04 0.69 0.69
β13 1.00 1.00 0.76 0.72 1.00 1.00 0.76 0.76
θ 1.00 1.00 1.12 1.14
β11 1.00 1.00 0.81 0.78 1.02 1.02 0.81 0.81
3 β12 1.00 1.00 0.76 0.74 1.04 1.04 0.77 0.77
β13 1.00 1.00 0.83 0.80 1.00 1.01 0.83 0.83
θ 1.00 1.00 1.10 1.13
β11 1.00 1.00 0.95 0.90 1.02 1.01 0.96 0.96
4 β12 1.00 1.00 0.94 0.88 1.03 1.03 0.95 0.95
β13 1.00 1.00 0.96 0.90 1.01 1.01 0.96 0.96
θ 1.00 1.00 1.09 1.09
β11 1.00 1.00 0.81 0.74 1.02 1.02 0.81 0.81
5 β12 1.00 1.00 0.77 0.70 1.03 1.03 0.77 0.77
β13 1.00 1.00 0.83 0.76 1.00 1.00 0.83 0.83
θ 1.00 1.00 1.09 1.09
β11 1.00 1.00 0.74 0.71 0.94 0.95 0.73 0.74
6 β12 1.00 1.00 0.72 0.69 0.96 0.97 0.71 0.72
β13 1.00 1.00 0.76 0.72 0.93 0.93 0.75 0.75
θ 1.00 1.00 0.89 0.90
a The SF models that adopt the independent gamma distributions for cluster-specific random effects
b The SF models that adopt the independent log-Normal distributions for cluster-specific random effects
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Table D.5: Average relative width of 95% credible/confidence intervals for β2, with the
Weibull-MVN model taken as the referent, across six simulation scenarios given in Table
3. Throughout values are based on results from R=500 simulated datasets.
Scenario Weibull Weibull Weibull Weibull PEM PEM Spline Spline
-MVN -DPM -SFG
a -SFLN
b -MVN -DPM -SFG -SFLN
β21 1.00 1.00 0.80 0.82 1.01 1.01 0.84 0.84
1 β22 1.00 1.00 0.75 0.78 1.02 1.02 0.79 0.79
β23 1.00 1.00 0.83 0.85 1.00 1.00 0.87 0.87
β21 1.00 1.00 0.77 0.77 1.01 1.01 0.78 0.78
2 β22 1.00 1.00 0.72 0.72 1.02 1.02 0.73 0.73
β23 1.00 1.00 0.80 0.80 1.00 1.00 0.80 0.80
β21 1.00 1.00 0.80 0.83 1.01 1.01 0.83 0.83
3 β22 1.00 1.00 0.75 0.78 1.02 1.03 0.79 0.79
β23 1.00 1.00 0.82 0.86 1.00 1.00 0.86 0.86
β21 1.00 1.00 0.90 0.90 1.01 1.01 0.96 0.96
4 β22 1.00 1.00 0.88 0.88 1.01 1.01 0.95 0.95
β23 1.00 1.00 0.91 0.91 1.00 1.00 0.97 0.97
β21 1.00 1.00 0.81 0.83 1.01 1.01 0.84 0.84
5 β22 1.00 1.00 0.77 0.78 1.02 1.02 0.79 0.79
β23 1.00 1.00 0.84 0.86 1.00 1.00 0.86 0.86
β21 1.00 1.00 0.78 0.79 0.96 0.96 0.82 0.82
6 β22 1.00 1.00 0.75 0.76 0.97 0.97 0.80 0.80
β23 1.00 1.00 0.79 0.80 0.95 0.95 0.84 0.84
a The SF models that adopt the independent gamma distributions for cluster-specific random effects
b The SF models that adopt the independent log-Normal distributions for cluster-specific random effects
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Table D.6: Average relative width of 95% credible/confidence intervals for β3, with the
Weibull-MVN model taken as the referent, across six simulation scenarios given in Table
3. Throughout values are based on results from R=500 simulated datasets.
Scenario Weibull Weibull Weibull Weibull PEM PEM Spline Spline
-MVN -DPM -SFG
a -SFLN
b -MVN -DPM -SFG -SFLN
β31 1.00 1.00 0.72 0.83 1.01 1.01 0.83 0.83
1 β32 1.00 1.00 0.73 0.83 1.01 1.02 0.83 0.83
β33 1.00 1.00 0.75 0.86 1.00 1.00 0.86 0.86
β31 1.00 1.00 0.77 0.75 1.01 1.01 0.77 0.77
2 β32 1.00 1.00 0.77 0.75 1.01 1.02 0.77 0.77
β33 1.00 1.00 0.81 0.79 1.00 1.00 0.81 0.81
β31 1.00 1.00 0.73 0.81 1.01 1.01 0.84 0.84
3 β32 1.00 1.00 0.74 0.81 1.01 1.02 0.84 0.84
β33 1.00 1.00 0.76 0.84 1.00 1.00 0.87 0.87
β31 1.00 1.00 0.85 0.97 1.01 1.01 0.98 0.98
4 β32 1.00 1.00 0.87 0.99 1.01 1.01 1.00 1.00
β33 1.00 1.00 0.85 0.96 1.00 1.00 0.97 0.97
β31 1.00 1.00 0.73 0.79 1.01 1.01 0.83 0.83
5 β32 1.00 1.00 0.73 0.80 1.01 1.01 0.83 0.84
β33 1.00 1.00 0.76 0.82 1.00 1.00 0.86 0.86
β31 1.00 1.00 0.69 0.69 0.96 0.96 0.69 0.69
6 β32 1.00 1.00 0.72 0.72 0.97 0.97 0.72 0.72
β33 1.00 1.00 0.73 0.73 0.94 0.94 0.73 0.73
a The SF models that adopt the independent gamma distributions for cluster-specific random effects
b The SF models that adopt the independent log-Normal distributions for cluster-specific random effects
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Table D.7: Mean squared error of prediction (×10−2) for cluster-specific random effects
based on six analyses described in Section 5.2, across six data scenarios given in Table 3.
Throughout values are based on results from R=500 simulated datasets.
Scenario Weibull Weibull Weibull Weibull PEM PEM Spline Spline
-MVN -DPM -SFG
a -SFLN
b -MVN -DPM -SFG -SFLN
%F %F† %F %F
V1 5.25 5.27 6.40 10355.30 5.27 5.27 6.39 10397.30
1 V2 7.66 7.70 8.70 17.8 11199.69 6.6 7.67 7.72 8.68 0.2 11131.71 0.8
V3 9.91 9.95 12.13 11221.04 9.91 9.96 12.11 11214.38
V1 6.36 6.41 8.10 10535.62 6.37 6.41 8.09 10476.70
2 V2 8.76 8.85 10.23 10.4 11328.83 7.8 8.77 8.86 10.20 0.0 11208.54 0.6
V3 11.13 11.19 13.85 11417.49 11.13 11.19 13.91 11449.00
V1 5.03 5.04 6.27 10398.49 5.04 5.04 6.22 10329.00
3 V2 6.34 6.34 8.28 15.8 11357.53 9.2 6.36 6.36 8.24 0.0 11348.16 0.6
V3 7.55 7.49 11.66 10932.18 7.57 7.55 11.69 10895.77
V1 3.84 3.85 4.99 9798.48 3.87 3.87 5.01 9765.63
4 V2 6.25 6.27 7.19 12.8 11076.72 12.4 6.25 6.27 7.12 0.4 11102.66 5.4
V3 7.89 7.90 9.57 10893.62 7.90 7.91 9.52 10886.70
V1 6.95 6.26 10.87 10005.24 6.96 6.27 10.86 9869.41
5 V2 11.52 10.50 14.95 12.8 11090.98 78.4 11.50 10.52 14.92 0.2 10976.78 76.4
V3 15.46 14.66 25.04 11156.06 15.46 14.72 24.94 11073.46
V1 5.05 5.01 6.34 9670.25 4.89 4.85 6.26 9804.42
6 V2 7.58 7.55 8.60 5.4 11259.19 9.2 7.41 7.39 8.49 1.4 11272.07 0.4
V3 6.72 6.65 13.42 10095.61 6.44 6.40 13.70 10233.22
a The SF models that adopt the independent gamma distributions for cluster-specific random effects
b The SF models that adopt the independent log-Normal distributions for cluster-specific random effects
† % of times SF models yield at least one of Vˆj being −∞, resulting in MSEP being ∞
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E Application to Medicare data from New England
In our main paper, posterior summaries for hazard ratio (HR) parameters for readmission,
exp(β1), from models for which a semi-Markov specification was adopted for h03(·) are
presented. In Table E.1-E.4, we provide posterior summaries for HR parameters for death
without readmission, exp(β2), and those for death following readmission, exp(β3), from
both Markov and semi-Markov models. We also provide the posterior estimates of exp(β1)
from Markov models in Table E.5.
From Table 4 (in the main paper) and Table E.1-E.5, we see the little difference in poste-
rior estimates of HR parameters between Markov and semi-Markov models in this particular
application. Therefore, our analyses in this document mainly focus on HR parameters for
death (exp(β2) and exp(β3)) under semi-Markov models. As seen in Table E.1 and Table
E.2, our proposed framework show how risk for death changes depending on whether or
not a patient experiences the readmission. For example, whereas there is evidence of an
increased risk of death for long hospital stay among individuals who have not been read-
mitted (HR 1.10; 95% CI 1.04, 1.18 in PEM-DPM), the same conclusion cannot be drawn
for individuals who have been readmitted (HR 0.98; 95% CI 0.87, 1.09 in PEM-DPM).
In addition, the association between death and two of covariates (age and Charlson/Deyo
score) is stronger in this magnitude (i.e. farther from zero) while the association between
death and some other covariates (sex, source of entry to initial hospitalization, length of
stay, discharged location, and whether or not patients underwent a procedure during the
hospitalization) is weakened among patient who have been readmitted. In general, our
analyses show evidence of increased risk for death for patients with male gender, older age,
initially hospitalized via some route other than ER, higher comorbidity score, a procedure
during the hospitalization, a discharge to a place other than home (without care).
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Table E.1: Posterior medians (PM) and 95% credible intervals (CI) for hazard ratio pa-
rameters for death without readmission (exp(β2)) from semi-competing risks data analyses
based on semi-Markov models.
Weibull-MVN Weibull-DPM PEM-MVN PEM-DPM
PM (95%CI) PM (95%CI) PM (95%CI) PM (95%CI)
Sex
Male 1.00 1.00 1.00 1.00
Female 0.69 (0.60, 0.79) 0.69 (0.61, 0.78) 0.75 (0.67, 0.83) 0.75 (0.67, 0.83)
Age∗ 1.09 (1.04, 1.13) 1.09 (1.04, 1.14) 1.07 (1.03, 1.11) 1.07 (1.03, 1.11)
Race
White 1.00 1.00 1.00 1.00
Non-white 0.93 (0.70, 1.22) 0.93 (0.70, 1.22) 0.94 (0.74, 1.17) 0.94 (0.75, 1.18)
Source of entry to initial
hospitalization
Emergency room 1.00 1.00 1.00 1.00
Other facility 1.61 (1.41, 1.85) 1.61 (1.41, 1.86) 1.50 (1.33, 1.70) 1.49 (1.32, 1.68)
Charlson/Deyo score
≤ 1 1.00 1.00 1.00 1.00
> 1 1.40 (1.12, 1.71) 1.39 (1.13, 1.73) 1.26 (1.08, 1.50) 1.27 (1.06, 1.51)
Procedure during hospitalization
No 1.00 1.00 1.00 1.00
Yes 0.09 (0.07, 0.12) 0.09 (0.07, 0.12) 0.13 (0.10, 0.16) 0.13 (0.10, 0.16)
Length of stay∗∗ 1.15 (1.07, 1.24) 1.15 (1.06, 1.24) 1.10 (1.04, 1.18) 1.10 (1.04, 1.18)
Care after discharge
Home 1.00 1.00 1.00 1.00
Home with care 2.41 (2.00, 2.91) 2.45 (2.02, 2.94) 2.22 (1.85, 2.63) 2.21 (1.90, 2.61)
Hospice 22.99 (18.08, 30.16) 23.71 (18.28, 31.20) 13.94 (11.22, 17.43) 13.85 (11.33, 17.08)
ICF/SNF 5.22 (4.29, 6.39) 5.33 (4.32, 6.45) 4.25 (3.57, 5.06) 4.25 (3.66, 5.01)
Other 4.81 (3.48, 6.70) 4.93 (3.58, 6.84) 3.79 (2.91, 4.98) 3.81 (2.94, 4.91)
∗ standardized so that 0 corresponds to an age of 77 years and so that one unit increment corresponds to 10 years
∗∗ standardized so that 0 corresponds to 10 days and so that one unit increment corresponds to 7 days
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Table E.2: Posterior medians (PM) and 95% credible intervals (CI) for hazard ratio param-
eters for death following readmission (exp(β3)) from semi-competing risks data analyses
based on semi-Markov models.
Weibull-MVN Weibull-DPM PEM-MVN PEM-DPM
PM (95%CI) PM (95%CI) PM (95%CI) PM (95%CI)
Sex
Male 1.00 1.00 1.00 1.00
Female 0.81 (0.66, 1.00) 0.81 (0.66, 0.98) 0.84 (0.70, 1.00) 0.84 (0.71, 1.01)
Age∗ 1.10 (1.02, 1.19) 1.10 (1.02, 1.19) 1.09 (1.02, 1.17) 1.09 (1.02, 1.17)
Race
White 1.00 1.00 1.00 1.00
Non-white 1.15 (0.77, 1.67) 1.14 (0.79, 1.65) 1.12 (0.79, 1.54) 1.11 (0.78, 1.54)
Source of entry to initial
hospitalization
Emergency room 1.00 1.00 1.00 1.00
Other facility 1.54 (1.25, 1.90) 1.55 (1.25, 1.91) 1.42 (1.17, 1.72) 1.42 (1.16, 1.72)
Charlson/Deyo score
≤ 1 1.00 1.00 1.00 1.00
> 1 1.51 (1.11, 2.06) 1.52 (1.11, 2.07) 1.41 (1.06, 1.85) 1.40 (1.05, 1.84)
Procedure during hospitalization
No 1.00 1.00 1.00 1.00
Yes 0.21 (0.15, 0.29) 0.21 (0.15, 0.29) 0.28 (0.20, 0.39) 0.28 (0.21, 0.39)
Length of stay∗∗ 1.01 (0.89, 1.13) 1.01 (0.89, 1.13) 0.98 (0.88, 1.09) 0.98 (0.87, 1.09)
Care after discharge
Home 1.00 1.00 1.00 1.00
Home with care 1.44 (1.13, 1.81) 1.44 (1.13, 1.82) 1.35 (1.08, 1.68) 1.34 (1.08, 1.65)
Hospice 10.23 (4.66, 22.01) 10.43 (4.83, 22.33) 6.46 (3.33, 12.58) 6.35 (3.30, 12.29)
ICF/SNF 2.54 (1.87, 3.45) 2.57 (1.87, 3.46) 2.08 (1.52, 2.77) 2.07 (1.56, 2.76)
Other 2.78 (1.64, 4.49) 2.72 (1.61, 4.44) 2.24 (1.40, 3.48) 2.25 (1.41, 3.43)
∗ standardized so that 0 corresponds to an age of 77 years and so that one unit increment corresponds to 10 years
∗∗ standardized so that 0 corresponds to 10 days and so that one unit increment corresponds to 7 days
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Table E.3: Posterior medians (PM) and 95% credible intervals (CI) for hazard ratio pa-
rameters for death without readmission (exp(β2)) from semi-competing risks data analyses
based on Markov models.
Weibull-MVN Weibull-DPM PEM-MVN PEM-DPM
PM (95%CI) PM (95%CI) PM (95%CI) PM (95%CI)
Sex
Male 1.00 1.00 1.00 1.00
Female 0.69 (0.60, 0.79) 0.69 (0.60, 0.79) 0.75 (0.67, 0.84) 0.75 (0.67, 0.83)
Age∗ 1.08 (1.04, 1.13) 1.08 (1.04, 1.13) 1.07 (1.03, 1.11) 1.07 (1.03, 1.11)
Race
White 1.00 1.00 1.00 1.00
Non-white 0.92 (0.69, 1.21) 0.92 (0.70, 1.22) 0.94 (0.75, 1.18) 0.94 (0.75, 1.16)
Source of entry to initial
hospitalization
Emergency room 1.00 1.00 1.00 1.00
Other facility 1.61 (1.42, 1.84) 1.62 (1.42, 1.86) 1.49 (1.32, 1.67) 1.49 (1.33, 1.69)
Charlson/Deyo score
≤ 1 1.00 1.00 1.00 1.00
> 1 1.40 (1.12, 1.73) 1.39 (1.12, 1.72) 1.26 (1.06, 1.49) 1.27 (1.06, 1.51)
Procedure during hospitalization
No 1.00 1.00 1.00 1.00
Yes 0.09 (0.07, 0.12) 0.09 (0.07, 0.12) 0.13 (0.10, 0.16) 0.13 (0.11, 0.17)
Length of stay∗∗ 1.15 (1.07, 1.23) 1.15 (1.07, 1.23) 1.10 (1.04, 1.17) 1.10 (1.04, 1.17)
Care after discharge
Home 1.00 1.00 1.00 1.00
Home with care 2.44 (2.04, 2.91) 2.42 (2.02, 2.93) 2.20 (1.86, 2.62) 2.20 (1.90, 2.61)
Hospice 23.52 (17.98, 30.13) 23.55 (18.05, 30.53) 13.72 (11.22, 17.49) 13.78 (11.10, 17.1)
ICF/SNF 5.30 (4.36, 6.43) 5.29 (4.38, 6.47) 4.23 (3.61, 5.16) 4.25 (3.62, 5.02)
Other 4.88 (3.59, 6.72) 4.87 (3.54, 6.73) 3.78 (2.93, 4.99) 3.82 (2.92, 4.97)
∗ standardized so that 0 corresponds to an age of 77 years and so that one unit increment corresponds to 10 years
∗∗ standardized so that 0 corresponds to 10 days and so that one unit increment corresponds to 7 days
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Table E.4: Posterior medians (PM) and 95% credible intervals (CI) for hazard ratio param-
eters for death following readmission (exp(β3)) from semi-competing risks data analyses
based on Markov models.
Weibull-MVN Weibull-DPM PEM-MVN PEM-DPM
PM (95%CI) PM (95%CI) PM (95%CI) PM (95%CI)
Sex
Male 1.00 1.00 1.00 1.00
Female 0.81 (0.66, 0.98) 0.81 (0.67, 0.99) 0.84 (0.71, 1.01) 0.85 (0.71, 1.02)
Age∗ 1.11 (1.02, 1.19) 1.10 (1.03, 1.20) 1.10 (1.03, 1.18) 1.09 (1.02, 1.18)
Race
White 1.00 1.00 1.00 1.00
Non-white 1.14 (0.78, 1.64) 1.15 (0.79, 1.67) 1.13 (0.81, 1.55) 1.14 (0.79, 1.58)
Source of entry to initial
hospitalization
Emergency room 1.00 1.00 1.00 1.00
Other facility 1.58 (1.28, 1.97) 1.58 (1.28, 1.97) 1.44 (1.18, 1.75) 1.46 (1.21, 1.77)
Charlson/Deyo score
≤ 1 1.00 1.00 1.00 1.00
> 1 1.53 (1.12, 2.11) 1.53 (1.12, 2.11) 1.40 (1.02, 1.84) 1.40 (1.06, 1.86)
Procedure during hospitalization
No 1.00 1.00 1.00 1.00
Yes 0.20 (0.14, 0.28) 0.20 (0.14, 0.28) 0.27 (0.19, 0.37) 0.27 (0.19, 0.36)
Length of stay∗∗ 1.00 (0.89, 1.13) 1.01 (0.89, 1.13) 0.98 (0.88, 1.09) 0.98 (0.88, 1.08)
Care after discharge
Home 1.00 1.00 1.00 1.00
Home with care 1.44 (1.15, 1.82) 1.44 (1.13, 1.81) 1.32 (1.06, 1.63) 1.33 (1.07, 1.66)
Hospice 11.81 (5.18, 25.66) 11.6 (5.08, 24.49) 6.95 (3.49, 12.75) 6.79 (3.24, 13.28)
ICF/SNF 2.70 (1.96, 3.68) 2.69 (1.99, 3.61) 2.12 (1.59, 2.81) 2.17 (1.63, 2.87)
Other 2.92 (1.74, 4.77) 2.89 (1.74, 4.68) 2.32 (1.46, 3.65) 2.36 (1.47, 3.67)
∗ standardized so that 0 corresponds to an age of 77 years and so that one unit increment corresponds to 10 years
∗∗ standardized so that 0 corresponds to 10 days and so that one unit increment corresponds to 7 days
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Table E.5: Posterior medians (PM) and 95% credible intervals (CI) for hazard ratio param-
eters for readmission (exp(β1)) from semi-competing risks data analyses based on Markov
models.
Weibull-MVN Weibull-DPM PEM-MVN PEM-DPM
PM (95%CI) PM (95%CI) PM (95%CI) PM (95%CI)
Sex
Male 1.00 1.00 1.00 1.00
Female 0.79 (0.70, 0.91) 0.80 (0.70, 0.91) 0.85 (0.76, 0.95) 0.85 (0.76, 0.95)
Age∗ 0.90 (0.86, 0.95) 0.90 (0.86, 0.95) 0.91 (0.87, 0.94) 0.91 (0.87, 0.95)
Race
White 1.00 1.00 1.00 1.00
Non-white 1.11 (0.86, 1.45) 1.11 (0.86, 1.44) 1.12 (0.89, 1.40) 1.11 (0.89, 1.38)
Source of entry to initial
hospitalization
Emergency room 1.00 1.00 1.00 1.00
Other facility 1.18 (1.03, 1.35) 1.19 (1.03, 1.36) 1.12 (0.99, 1.26) 1.12 (0.99, 1.27)
Charlson/Deyo score
≤ 1 1.00 1.00 1.00 1.00
> 1 1.49 (1.19, 1.84) 1.50 (1.19, 1.85) 1.40 (1.15, 1.68) 1.39 (1.15, 1.68)
Procedure during hospitalization
No 1.00 1.00 1.00 1.00
Yes 0.45 (0.37, 0.53) 0.45 (0.37, 0.53) 0.57 (0.49, 0.66) 0.57 (0.48, 0.66)
Length of stay∗∗ 1.15 (1.07, 1.23) 1.15 (1.07, 1.23) 1.12 (1.05, 1.19) 1.12 (1.05, 1.19)
Care after discharge
Home 1.00 1.00 1.00 1.00
Home with care 0.95 (0.82, 1.11) 0.95 (0.82, 1.11) 0.89 (0.78, 1.02) 0.89 (0.78, 1.01)
Hospice 0.39 (0.23, 0.62) 0.38 (0.22, 0.64) 0.27 (0.16, 0.42) 0.27 (0.16, 0.43)
ICF/SNF 0.88 (0.73, 1.06) 0.88 (0.73, 1.07) 0.76 (0.63, 0.90) 0.76 (0.64, 0.90)
Other 1.05 (0.77, 1.43) 1.04 (0.77, 1.45) 0.89 (0.68, 1.18) 0.89 (0.67, 1.18)
∗ standardized so that 0 corresponds to an age of 77 years and so that one unit increment corresponds to 10 years
∗∗ standardized so that 0 corresponds to 10 days and so that one unit increment corresponds to 7 days
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For our proposed models, we assess the convergence of our MCMC scheme by evaluating
the potential scale reduction factor (PSRF) of Gelman et al. (2013). The potential problem
with PSRF is that it has not converged but happens to be close to 1 by chance even though
the PSRF is actually fluctuating. Therefore, for each parameter, the PSRF was calculated
at several points in time with the first half discarded as burn-in. Then, we summarize
the results using mean, maximum, and minimum value of PSRF for all model parameters
at different iterations. The results are shown in Figure E.1. As the number of MCMC
iterations increases, the mean PSRF converges toward 1 and the maximum of PSRF is less
than 1.05 indicating that all model parameters have converged well.
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Figure E.1: The mean, maximum, and minimum value of the potential scale reduction
factor (PSRF) of all model parameters from the analysis of Medicare data.
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